US20130171185A1 - Norovirus derived immunogenic compositions and methods - Google Patents

Norovirus derived immunogenic compositions and methods Download PDF

Info

Publication number
US20130171185A1
US20130171185A1 US13/808,157 US201113808157A US2013171185A1 US 20130171185 A1 US20130171185 A1 US 20130171185A1 US 201113808157 A US201113808157 A US 201113808157A US 2013171185 A1 US2013171185 A1 US 2013171185A1
Authority
US
United States
Prior art keywords
norovirus
gii
chimeric
strain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/808,157
Other languages
English (en)
Inventor
Ethan Settembre
Angelica Medina-Selby
Doris Coit
Philip R. Dormitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/808,157 priority Critical patent/US20130171185A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DORMITZER, PHILIP, SETTEMBRE, ETHAN, COIT, DORIS, MEDINA-SELBY, ANGELICA
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Publication of US20130171185A1 publication Critical patent/US20130171185A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]

Definitions

  • Noroviruses are the primary etiological agents of acute viral gastroenteritis in adults and children. noroviruses are highly infectious and spread by ingestion of contaminated food, such as oysters and water. Noroviruses also spread rapidly by person-to-person transmission through the fecal-oral route in semiclosed communities, such as hospitals, schools, nursing homes, and cruise ships. These characteristics make noroviruses a major public health concern. For example, in the United States alone, noroviruses cause greater than 95% of viral gastroenteritis outbreaks and an estimated 23 million cases of gastroenteritis per year (Fankhauser et al. (2002) J. Infect. Dis. 186:1-7; MMWR Morb. Mortal Weekly Rep. (2000) 49:207-211).
  • the symptoms of norovirus infection include diarrhea and vomiting as well as fever, headaches, chills and stomach-aches.
  • the cause of such symptoms may be related to the binding of noroviruses to carbohydrate receptors of intestinal epithelial cells, which results in an imbalance in ion transfer (Marionneau et al. (2002) Gastroenterology 122:1967-1977; Hutson et al. (2003) J. Virol. 77:405-415).
  • Extremely contagious, noroviruses can cause disease by infection with as few as 10 virions. Although otherwise healthy, people infected with noroviruses may recover within 2-4 days, they may still shed virus for up to 2 weeks after the onset of symptoms. Approximately 30-40% of infected people may remain symptom-free but spread infection by shedding of virus to others who may be more susceptible to infection (Hutson et al. (2004) Trends Microbiol. 12(6):279-287).
  • Noroviruses are members of the Caliciviridae family of small, non-enveloped, icosahedral viruses, 27-40 nm in diameter, containing a single-strand of positive-sense RNA.
  • Phylogenic studies show that the genus Norovirus is made up of at least 40 diverse virus strains categorized into 5 genogroups, GI-GV, on the basis of sequence similarity.
  • GI and GII are the most important genogroups for human infection. Each genogroup is further divided into genotypes.
  • GI includes 8 distinct genotypes and GII has at least 17 different genotypes.
  • strains in a genogroup have 51-56% nucleotide sequence identity, and strains in a genotype have 69-70% nucleotide sequence similarity (Donaldson et al., Nat. Rev. Microbiol. 2010 Feb. 2. [e-pub ahead of print]).
  • Norovirus RNA includes three open reading frames (ORFs), which encode the structural and non-structural proteins of the virus.
  • the major structural protein of noroviruses is viral protein 1 (VP1). It is exclusively encoded by ORF2 of the norovirus RNA and forms the norovirus capsid structure.
  • the norovirus capsid is made up of 180 copies of VP1 monomers. When VP1 is expressed recombinantly, it can self-assemble into an icosahedral capsid structure that lacks a viral genome and is known as virus-like particle (VLP).
  • VLP virus-like particle
  • each capsid protein, VP1 is made up of two distinct domains, the shell (S) domain and the protruding (P) domain. These two domains are tethered together by a short flexible linker or hinge.
  • the S-domains of the VP1 monomers collectively form the core of the norovirus VLP, and the P-domains extend radially on the surface of VLP and include the bulk of the known antigenic epitopes of norovirus.
  • the P domain (aa 226-530, Norwalk strain numbering) is divided into two subdomains, P1 and P2.
  • the P2 domain is located at the outermost surface of the virion (or VLP) radially and is considered to be hypervariable in sequence.
  • the P2 domain is the least conserved region of VP1 among norovirus strains and is thought to play an important role in receptor binding and immune reactivity.
  • Norwalk virus VLPs The expression and self-assembly of Norwalk virus VLPs was first demonstrated using the baculovirus-infected insect cell expression system (Jiang et al. (1992) J. Virol. 66:6527-6532) and then using a Venezuelan equine encephalitis vector-infected mammalian cell expression system (Baric et al. (2002) J. Virol. 76:3025-3030).
  • the VP1 monomers in Norwalk virus, and certain other noroviruses self-assemble into VLPs that structurally mimic native norovirus virions.
  • VLPs preserve the authentic conformation of the viral capsid protein but lack norovirus genetic material. When injected into animals, norovirus VLPs can elicit an appropriate host immune response.
  • Virol 81:9932-9941 A third reason is the lack of a cell culture model for human noroviruses, preventing the development of a neutralization assay. A fourth reason is the lack of an animal model for human noroviruses, limiting preclinical testing of vaccine efficacy and impeding research to understand norovirus pathogensis and immunity (Donaldson et al. (2010) Nature Rev. Microbiol. 8:231-241).
  • VLPs containing either one type of VP1 protein from only one norovirus strain (also known as monovalent VLPs) or a mixture of non-chimeric VP1 proteins from two or more norovirus strains (also known as multivalent VLPs) have been prepared. See, e.g., WO2009039229.
  • Monovalent VLPs may be less effective against a broad range of norovirus strains than multivalent VLPs.
  • Current multivalent VLPs may be constrained in the range of VP1's from different strains that can be co-assembled due to their differences in VP1-VP1 interaction surfaces between strains. Because of these problems, neither of the above-mentioned vaccine systems are suitable for rapid customization against the new noroviruses that emerge due to viral evolution.
  • Noroviruses undergo progressive changes in antigenic type, with new antigenic variants replacing older antigenic variants. Therefore, it is likely that there will be a need to periodically change the strain composition of a norovirus vaccine, as is done today for seasonal influenza vaccines.
  • the assembly of VLPs from VP1 of different norovirus strains occurs with different levels of efficiency, and the resulting VLPs have different levels of yield and stability. This variability between strains would impede the speed, reliability, and facility of needed strain changes in a norovirus vaccine composition.
  • the present invention provides immunogenic compositions comprising norovirus antigens and materials and methods that can be used for rapid development of such compositions.
  • the norovirus antigens of the invention comprise chimeric norovirus VP1 proteins in which all or a portion of the P-domain is replaced with all or a portion of a P-domain from a different norovirus strain.
  • the invention relates to a chimeric norovirus viral protein 1 (VP1), which contains the S-domain of VP1 from a first norovirus strain and at least a portion of the P-domain of VP1 from a second norovirus strain, and optionally, a linker peptide that operably links the S-domain and the P-domain.
  • the linker peptide can be any suitable linker, such as the linker peptide of the VP1 from the first norovirus strain, from the second norovirus strain, or from a third norovirus strain.
  • the chimeric VP1 can have a structure according to Formula (I): A-S-L-P-B (I).
  • a and B are independently absent or any desired amino acid sequence; S is the S-domain of VP1 from a first norovirus strain; L is absent or a linker peptide; and P is a norovirus VP1 P-domain; wherein at least a portion of the P-domain is from a second norovirus strain.
  • P is the P-domain from a second norovirus strain. In other embodiments, P comprises a P1-subdomain, or portion thereof, from the first norovirus strain and a P2-subdomain from a second norovirus strain.
  • the chimeric VP1 protein can contain portions, e.g., S-domain, P-domain, from any desired norovirus strain, such as the norovirus strains listed in Table 1.
  • the S-domain is from the Snow Mountain strain.
  • the P-domain or a portion thereof e.g., P2 subdomain
  • the S-domain is from the Snow Mountain strain and the P-domain or a portion thereof (e.g., P2 subdomain) is from a different norovirus strain from genogroup GII, a norovirus strain from genogroup GI or a norovirus strain from genogroup GIV.
  • the S-domain is from the Snow Mountain strain and the P-domain or a portion thereof (e.g., P2 subdomain) is from Norwalk virus, GII.4.2006a, or New Orleans.
  • the invention in another aspect, relates to a norovirus virus like particle (VLP) comprising a chimeric VP1 protein as described herein.
  • VLP can be monovalent or multivalent.
  • the multivalent VLP can comprise two or more different chimeric VP1 protein as described herein.
  • the multivalent VLP can comprise a chimeric VP1 protein as described herein and a naturally occurring norovirus VP1 protein.
  • the invention also relates to recombinant nucleic acids that encode a chimeric norovirus VP1 protein as described herein.
  • the recombinant nucleic acid can be, for example, RNA or DNA, and if desired, can comprise a vector.
  • the recombinant nucleic acid is self-replicating, such as a self-replicating RNA.
  • the invention in another aspect, relates to immunogenic compositions comprising a chimeric norovirus VP1 protein as described herein, a VLP as described herein or combinations thereof.
  • the invention also relates to an immunogenic composition comprising a recombinant nucleic acid that encodes encode a chimeric norovirus VP1 protein as described herein.
  • the invention in another aspect, relates to a recombinant host cell comprising a recombinant nucleic acid that encodes encode a chimeric norovirus VP1 protein as described herein.
  • the host cell can be, for example, insect cells, mammalian cells, avian cells, bacteria, yeast cells, Tetrahymena cells and combinations thereof.
  • the invention also relates to a method of producing a chimeric norovirus VP1 protein and/or VLP, comprising culturing a recombinant host cell as described herein under conditions whereby the recombinant nucleic acid is expressed and chimeric VP1 protein is produced.
  • the recombinant host cell is maintained under conditions suitable for formation of VLPs.
  • the method further comprises isolating the chimeric norovirus VP1 protein and/or VLPs from the culture media and/or the recombinant host cells.
  • FIG. 1 depicts the diagram for vector pMADC5 suitable for subcloning and amplification of the chimeric VP1 oligonucleotides of the invention.
  • FIG. 2 depicts the diagram of a vector pBS24.1 suitable for expression of chimeric VP1 proteins and VLPs in S. cerevisiae.
  • FIG. 3 is an amino acid alignment of VP1 proteins from three different norovirus strains, Norwalk (norw) genotype G1.1 (SEQ ID NO:11), Snow Mountain (snow) genotype GII.2 (SEQ ID NO:12), and 2006a (g2.4) GII.4 (SEQ ID NO:13).
  • the shell domain (S-domain) is residues 1-221
  • the linker peptide is residues 222-230
  • the protruding domain (P-domain) is residues 231-530.
  • FIG. 4A depicts the nucleotide sequence (SEQ ID NO:14) of ORF2 in norovirus strain Snow Mountain, which encodes the VP1 protein in that strain.
  • FIG. 4B show the translated amino acid sequence (SEQ ID NO:12) of VP1 protein encoded by ORF2 of Snow Mountain.
  • FIG. 5 depicts a nucleic acid (SEQ ID NO:15) encoding a chimeric VP1 protein whose S-domain is derived from the Snow Mountain strain, and P-domain is derived from the Norwalk strain.
  • FIG. 6 depicts a nucleic acid (SEQ ID NO:16) encoding a chimeric VP1 protein whose S-domain is derived from the Snow Mountain strain, and P-domain is derived from the GII.4 2006a strain.
  • FIG. 7 shows 24 schematic representations of the primary structure of exemplary chimeric VP1 proteins of the invention.
  • the variables A, S, L, P1-1, P2, P1-2, and B are as described herein.
  • FIGS. 8A-8E show a multiple amino acid alignment of VP1 sequences of several norovirus strains. See, Hansman et al. (2006) J. General Virology 87:909-919. The following regions are indicated in these figures: N-terminal region (line); S-domain (filled box), P 1-1 -subdomain (open box); P 2 -subdomain (XXX); P 1-2 -subdomain (open box) and C-terminal region (line). Asterisks indicate conserved amino acids.
  • sequences depicted are from the following norovirus strains: #8 (SEQ ID NO:17) (AB058547, a GI/11 strain); SeV (SEQ ID NO:18) (AB031013, a GI/1 strain); 258 (SEQ ID NO:19) (AB078335, a GI/2 strain); 645 (SEQ ID NO:20) (BD011871, a GI/3 strain); CV (SEQ ID NO:21) (AB042808, a GI/4 strain); WUG1 (SEQ ID NO:22) (AB081723, a GI/8 strain); HV (SEQ ID NO:23) (U07611, a GII/1 strain); 485 (SEQ ID NO:24) (DQ093065, a GII/1 strain); Ina (SEQ ID NO:25) (AB195225, a GII/2 strain); 809 (SEQ ID NO:26) (BD011876, a GII/3 strain); Sh5 (SEQ ID NO:27) (
  • FIG. 9 is a table showing amino acid residues identified by Chakavarty et al. (2005) J. Virology, 79(1):554-568, from S and P domains, that distinguish different known and suggested antigenic norovirus strains and classes.
  • FIG. 10A is an X-ray structure of Norwalk virus-like particles with the S-domain (internal) in dark gray and the P-domain (external) in light grey.
  • FIG. 10B is a view of a single monomer colored as in FIG. 10A .
  • FIG. 11A is an image depicting a purified protein of Snow Mountain VLPs.
  • FIG. 11B is an electron micrograph of Snow Mountain VLPs.
  • FIG. 12A is an image depicting a purified protein of Snow Mountain/Norwalk VLP chimera.
  • FIG. 12B is an electron micrograph of Snow Mountain/Norwalk chimeric VLPs.
  • the present invention provides compositions and methods for production and use of chimeric norovirus VP1 proteins.
  • the invention further provides immunogenic compositions that include norovirus VLPs comprising said chimeric VP1 proteins in which the S-domain is derived from a first norovirus strain and all or part of the P-domain is derived from a second norovirus strain.
  • nucleic acids and polypeptides include nucleic acids and polypeptides, and methods for preparing and purifying such nucleic acids and polypeptides. These aspects of the invention together with the VLPs of the invention and their use in immunogenic compositions and methods of using such compositions in the treatment or prevention of norovirus are described in more detail below.
  • a includes singular and plural references unless the content clearly dictates otherwise.
  • reference to “a polynucleotide” includes a mixture of two or more such polynucleotides, and the like.
  • norovirus and “Norwalk-like virus” refer to members of the genus norovirus of the family Caliciviridae of positive-sense, single-stranded RNA, nonenveloped viruses (Green et al., Human Caliciviruses, in Fields Virology Vol. 1, pp. 841-874 (Knipe and Howley, editors-in-chief, 4th ed., Lippincott Williams & Wilkins 2001)).
  • the term norovirus includes strains in all genogroups of the virus. Currently, norovirus strains are divided into five genogroups (GI-GV), which are subdivided into at least 20 genetic clusters or genotypes.
  • norovirus includes, but is not limited to, the species Norwalk virus (NV), Lordsdale virus (LV), Mexico virus (MV), Hawaii virus (HV), Snow Mountain virus (SMV), Desert Shield virus (DSV), and Southhampton virus (SV).
  • NV Norwalk virus
  • LV Lordsdale virus
  • MV Mexico virus
  • HV Hawaii virus
  • SMV Snow Mountain virus
  • DSV Desert Shield virus
  • SV Southhampton virus
  • a large number of norovirus isolates have been partially or completely sequenced. See, e.g., the GenBank database (ncbi.nlm.nih.gov), the Taxonomy Database at National Center for Biotechnology Information (ncbi.nlm.nih.gov) or the PathoSystems Resource Integration Center Database on Caliciviridae (patric.vbi.vt.edu).
  • the term norovirus also includes isolates not characterized at the time of filing.
  • polypeptide and “protein” refer to a polymer of amino acid residues and are not limited to a minimum length of the product. Thus, peptides, oligopeptides, dimers, multimers, and the like, are included within the definition. Both full-length proteins and fragments thereof are encompassed by the definition.
  • the terms also include postexpression modifications of the polypeptide, for example, glycosylation, acetylation, phosphorylation and the like.
  • a “polypeptide” refers to a protein which includes modifications, such as deletions, additions and substitutions (generally conservative in nature), to the native sequence, so long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
  • substantially purified generally refers to isolation of a substance (compound, polynucleotide, protein, polypeptide, polypeptide composition) such that the substance comprises the majority percent of the sample in which it resides.
  • a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample.
  • Techniques for purifying polynucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density.
  • isolated is meant, when referring to a polypeptide, that the indicated molecule is separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro-molecules of the same type.
  • isolated with respect to a polynucleotide is a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences in association therewith; or a molecule disassociated from the chromosome.
  • Recombinant as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation, is not associated with all or a portion of the polynucleotide with which it is associated in nature.
  • the term “recombinant” as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide.
  • the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions.
  • transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transfection, transduction or f-mating are included.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
  • Recombinant host cells refer to cells which can be, or have been, used as recipients for recombinant vector or other transferred DNA, and include the original progeny of the original cell which has been transfected.
  • a “coding sequence” or a sequence which “encodes” a selected polypeptide is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or “control elements”).
  • the boundaries of the coding sequence can be determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxy) terminus
  • a coding sequence can include, but is not limited to, cDNA from viral, procaryotic or eucaryotic mRNA, genomic DNA sequences from viral or procaryotic DNA or RNA, and even synthetic DNA sequences.
  • a transcription termination sequence may be located 3′ to the coding sequence.
  • control elements include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3′ to the translation stop codon), sequences for optimization of initiation of translation (located 5′ to the coding sequence), and translation termination sequences.
  • nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones (e.g. phosphorothioates, etc.), and also peptide nucleic acids (PNA), etc.
  • the invention includes nucleic acids comprising sequences complementary to those described above (e.g. for antisense or probing purposes).
  • self-replicating refers to a nucleic acid molecule that encodes a polymerase, contains nucleotide sequence elements that enable that polymerase to replicate the nucleic acid molecule and, preferably, also encodes a desired polypeptide, such as a chimeric norovirus VP1.
  • the self-replication nucleic acid is a self-replicating RNA molecule.
  • a self-replicating RNA molecule can be based on an alphavirus genome, and encode nonstructural proteins that can direct replication of the RNA molecule, contains a replication recognition sequence sufficient to allow replication of the RNA molecule, and also encode a desired target polypeptide, such as such as a chimeric norovirus VP1.
  • one or more structural viral genes are deleted or omitted from the self-replicating RNA molecule.
  • Suitable alphaviruses that can be used to produce self-replicating RNA molecules include Sindbis virus, Semliki forest virus, Eastern Equine Encephalitis virus, Venezuelan equine encephalitis virus and the like. (See, e.g., EP 1 751 289 B1; Ying et al. (1999) Nat. Med. 5(7):823-827; Racanelli et al. (2004) Immunity, 20(1):47-58, regarding self-replicating RNA molecules.)
  • “Operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function.
  • a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper enzymes are present.
  • the promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof.
  • intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.
  • Encoded by refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 amino acids.
  • “Expression cassette” or “expression construct” refers to an assembly which is capable of directing the expression of the sequence(s) or gene(s) of interest.
  • An expression cassette generally includes control elements, as described above, such as a promoter which is operably linked to (so as to direct transcription of) the sequence(s) or gene(s) of interest, and often includes a polyadenylation sequence as well.
  • the expression cassette described herein may be contained within a plasmid construct.
  • the plasmid construct may also include, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a M13 origin of replication), at least one multiple cloning site, and a “mammalian” origin of replication (e.g., a SV40 or adenovirus origin of replication).
  • a signal which allows the plasmid construct to exist as single-stranded DNA e.g., a M13 origin of replication
  • at least one multiple cloning site e.g., a SV40 or adenovirus origin of replication
  • “Purified polynucleotide” refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about at least 90%, of the protein with which the polynucleotide is naturally associated.
  • Techniques for purifying polynucleotides of interest include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.
  • a “vector” is capable of transferring nucleic acid sequences to target cells (e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes).
  • target cells e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes.
  • vector construct e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes.
  • expression vector e transfer vector
  • the term includes cloning and expression vehicles, as well as viral vectors.
  • epitope generally refers to the site on an antigen which is recognized by a T-cell receptor and/or an antibody. It may be a short peptide derived from or as part of a protein antigen. The three-dimensional structure of the epitope may or may not be important for its function. However the term is also intended to include peptides with glycopeptides and carbohydrate epitopes. Several different epitopes may be carried by a single antigenic molecule. The term “epitope” also includes modified sequences of amino acids or carbohydrates which stimulate responses which recognize the whole organism. It is advantageous if the selected epitope is an epitope of an infectious agent, which causes the infectious disease.
  • Hardy et al. have identified epitopes of the Norwalk virus capsid protein at residues 133-137 and of the Snow Mountain virus capsid protein at residues 319-327, comprising the following sequences: WTRGSHNL, (SEQ ID NO:1), WTRGGHGL, (SEQ ID NO:2), WTRGQHQL (SEQ ID NO:3), or WLPAPIDKL (SEQ ID NO:4).
  • Immunogenic polypeptides comprising such capsid epitopes and nucleic acids encoding them may be used in the practice of the invention.
  • T cell epitope refers generally to those features of a peptide structure which are capable of inducing a T cell response and a “B cell epitope” refers generally to those features of a peptide structure which are capable of inducing a B cell response.
  • an “immunological response” to an antigen or composition is the development in a subject of a humoral and/or a cellular immune response to an antigen present in the composition of interest.
  • a “humoral immune response” refers to an immune response mediated by antibody molecules
  • a “cellular immune response” is one mediated by T-lymphocytes and/or other white blood cells.
  • CTLs cytolytic T-cells
  • CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells.
  • MHC major histocompatibility complex
  • helper T-cells help induce and promote the destruction of intracellular microbes, or the lysis of cells infected with such microbes.
  • Another aspect of cellular immunity involves an antigen-specific response by helper T-cells.
  • Helper T-cells act to help stimulate the function, and focus the activity of, nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface.
  • a “cellular immune response” also refers to the production of cytokines, chemokines and other such molecules produced by activated T-cells and/or other white blood cells, including those derived from CD4+ and CD8+ T-cells.
  • An immunogenic composition or vaccine that elicits a cellular immune response may serve to sensitize a vertebrate subject by the presentation of antigen in association with MHC molecules at the cell surface.
  • the cell-mediated immune response is directed at, or near, cells presenting antigen at their surface.
  • antigen-specific T-lymphocytes can be generated to allow for the future protection of an immunized host.
  • the ability of a particular antigen to stimulate a cell-mediated immunological response may be determined by a number of assays, such as by lymphoproliferation (lymphocyte activation) assays, CTL cytotoxic cell assays, or by assaying for T-lymphocytes specific for the antigen in a sensitized subject.
  • assays are well known in the art. See, e.g., Erickson et al. (1993) J. Immunol. 151:4189-4199; Doe et al. (1994) Eur. J. Immunol. 24:2369-2376.
  • Recent methods of measuring cell-mediated immune response include measurement of intracellular cytokines or cytokine secretion by T-cell populations, or by measurement of epitope specific T-cells (e.g., by the tetramer technique) (reviewed by McMichael, A. J. and O'Callaghan, C. A. (1998) J. Exp. Med. 187(9)1367-1371; Mcheyzer-Williams, M. G. et al. (1996), Immunol. Rev. 150:5-21; Lalvani, A. et al. (1997) J. Exp. Med. 186:859-865).
  • an immunological response as used herein may be one that stimulates the production of antibodies (e.g., neutralizing antibodies that block bacterial toxins and pathogens such as viruses entering cells and replicating by binding to toxins and pathogens, typically protecting cells from infection and destruction).
  • the antigen of interest may also elicit production of CTLs.
  • an immunological response may include one or more of the following effects: the production of antibodies by B-cells; and/or the activation of suppressor T-cells and/or memory/effector T-cells directed specifically to an antigen or antigens present in the composition or vaccine of interest.
  • responses may serve to neutralize infectivity, and/or mediate antibody-complement, or antibody dependent cell cytotoxicity (ADCC) to provide protection to an immunized host.
  • ADCC antibody dependent cell cytotoxicity
  • the innate immune system of mammals also recognizes and responds to molecular features of pathogenic organisms via activation of Toll-like receptors and similar receptor molecules on immune cells.
  • various non-adaptive immune response cells are activated to, e.g., produce various cytokines, lymphokines and chemokines.
  • Cells activated by an innate immune response include immature and mature Dendritic cells of the monocyte and plasmacytoid lineage (MDC, PDC), as well as gamma, delta, alpha and beta T cells and B cells and the like.
  • MDC monocyte and plasmacytoid lineage
  • the present invention also contemplates an immune response wherein the immune response involves both an innate and adaptive response.
  • an “immunogenic composition” is a composition that comprises an antigenic molecule where administration of the composition to a subject results in the development in the subject of a humoral and/or a cellular immune response to the antigenic molecule of interest.
  • immunogenic protein or polypeptide refer to an amino acid sequence which elicits an immunological response as described above.
  • An “immunogenic” protein or polypeptide, as used herein, includes the full-length natural or recombinant sequence of the protein in question, including the precursor and mature forms, analogs thereof, or immunogenic fragments thereof.
  • a norovirus polynucleotide, oligonucleotide, nucleic acid, protein, polypeptide, or peptide, as defined above, is a molecule derived from a norovirus, respectively, including, without limitation, any of the various isolates of norovirus.
  • the molecule need not be physically derived from the particular isolate in question, but may be synthetically or recombinantly produced.
  • ORF1 which is transcribed into a polyprotein
  • ORF2 which is transcribed into the major capsid protein VP1
  • ORF3 which is transcribed into the minor structural protein VP2.
  • the boundaries of the polypeptide domains within the VP1 protein are as follows: the shell (S) domain formed by amino acid residues 1-221, a flexible hinge region at amino acid residues 222-230, and the protruding (P) domain formed by amino residues 231-530.
  • the P-domain is further divided into two subdomains, P1 and the hypervariable P2, which extends farthest out from the capsid shell and contains the putative receptor-binding sites (Choi, et al. (2008) Proc. Natl. Acad. Sci. USA 105:9175-9180, Prasad et al. (1999) Science 286:287-290).
  • the foregoing numbering is relative to the polyprotein amino acid sequence of Norwalk strain (SEQ ID NO:11), it is to be understood that the corresponding amino acid positions in sequences obtained from other genotypes and isolates of norovirus are also intended to be encompassed by the present invention. For example, see FIG. 3 .
  • any one of the polypeptides encoding the full-length VP1 or VP2, as well as variants thereof, immunogenic fragments thereof, and nucleic acids encoding such polypeptides, variants or immunogenic fragments can be used in the practice of the invention.
  • NCBI National Center for Biotechnology Information
  • GenBank Accession No. AY126475 Norwalk-like virus isolate Bo/Dumfries/94/UK, GenBank Accession No. AY126474; norovirus NLV/IF2036/2003/Iraq, GenBank Accession No. AY675555; norovirus NLV/IF1998/2003/Iraq, GenBank Accession No. AY675554; norovirus NLV/BUDS/2002/USA, GenBank Accession No. AY660568; norovirus NLV/Paris Island/2003/USA, GenBank Accession No. AY652979; Snow Mountain virus, complete genome, GenBank Accession No. AY134748; Norwalk-like virus NLV/Fort Lauderdale/560/1998/US, GenBank Accession No.
  • AF414420 Norwalk-like virus NLV/Richmond/283/1994/US, GenBank Accession No. AF414419; Norwalk-like virus NLV/Westover/302/1994/US, GenBank Accession No. AF414418; Norwalk-like virus NLV/UK3-17/12700/1992/GB, GenBank Accession No. AF414417; Norwalk-like virus NLV/Miami/81/1986/US, GenBank Accession No. AF414416; Snow Mountain strain, GenBank Accession No. U70059; Desert Shield virus DSV395, GenBank Accession No. U04469; Norwalk virus, complete genome, GenBank Accession No. AF093797; Hawaii calicivirus, GenBank Accession No.
  • the terms “major capsid protein” or “major capsid polypeptide” or “VP1” in reference to a norovirus refer to a polypeptide comprising a sequence homologous or identical to the ORF2-encoded polypeptide of a norovirus, and includes sequences displaying at least about 70-100% or about 80-100% amino acid sequence identity thereto, including any percent identity within this range, such as 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% amino acid sequence identity thereto.
  • the terms “minor structural protein” or “minor structural polypeptide” or “VP2” or “small basic protein” in reference to a norovirus refer to a polypeptide comprising a sequence homologous or identical to the ORF3-encoded polypeptide of a norovirus, and includes sequences displaying at least about 70-100% or about 80-100% amino acid sequence identity thereto, including any percent identity within this range, such as 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% amino acid sequence identity thereto.
  • virus-like particle refers to a nonreplicating, noninfectious viral shell, that contains a viral capsid but lacks all or part of the viral genome, in particular, the replicative and infectious components of the viral genome.
  • VLPs are generally composed of one or more viral proteins, such as, but not limited to those proteins referred to as capsid, coat, shell, surface, structural proteins (e.g., VP1, VP2).
  • norovirus VLPs can form spontaneously upon recombinant expression of VP1 in an appropriate expression system. Methods for producing particular VLPs are known in the art and discussed more fully below.
  • VLPs following recombinant expression of viral proteins can be detected using conventional techniques known in the art, such as by electron microscopy, biophysical characterization, and the like.
  • VLPs can be isolated by density gradient centrifugation and/or identified by characteristic density banding.
  • cryoelectron microscopy can be performed on vitrified aqueous samples of the VLP preparation in question, and images recorded under appropriate exposure conditions.
  • Negative stained electron microscopy can be performed on norovirus or norovirus VLP samples after coating with an electron-dense negative contrast agent, such as uranyl acetate, uranuyl formate, or phosphotungstic acid.
  • an electron-dense negative contrast agent such as uranyl acetate, uranuyl formate, or phosphotungstic acid.
  • a “biological sample” refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, blood, plasma, serum, fecal matter, urine, bone marrow, bile, spinal fluid, lymph fluid, samples of the skin, external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, organs, biopsies and also samples of in vitro cell culture constituents including but not limited to conditioned media resulting from the growth of cells and tissues in culture medium, e.g., recombinant cells, and cell components.
  • norovirus may be obtained from biological samples such as vomit or diarrhea from individuals infected with the viruses.
  • subject any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
  • farm animals such as cattle, sheep, pigs, goats and horses
  • domestic mammals such as dogs and cats
  • laboratory animals including rodents such as mice, rats and guinea pigs
  • birds including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
  • the term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
  • “Homology” refers to the percent identity between two polynucleotide or two polypeptide moieties.
  • Two nucleic acid, or two polypeptide sequences are “substantially homologous” to each other when the sequences exhibit at least about 50% sequence identity, preferably at least about 75% sequence identity, more preferably at least about 80%-85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules.
  • substantially homologous also refers to sequences showing complete identity to the specified sequence.
  • identity refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M. O. in Atlas of Protein Sequence and Structure M. O. Dayhoff ed., 5 Suppl.
  • nucleotide sequence identity is available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, Wis.) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above. For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions.
  • Another method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, Calif.). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the “Match” value reflects “sequence identity.”
  • Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters.
  • homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
  • DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art.
  • Amino acid substitutions when present in the chimeric VP1 proteins, are preferably conservative in nature, i.e., substitutions in which a first amino acid is replaced with a second amino acid that have similar properties based on their side chains. Specifically, amino acids are generally divided into four families and substitutions with families are considered to be conservative substitutions.
  • the four families are: (1) acidic amino acids—aspartate and glutamate; (2) basic amino acids—lysine, arginine, histidine; (3) non-polar amino acids—alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar amino acids—glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.
  • terapéuticaally effective amount in the context of the immunogenic compositions is meant an amount of an immunogen (e.g., chimeric VP1 protein, VLP, or nucleic acid encoding an antigen) which will induce an immunological response, either for antibody production or for treatment or prevention of norovirus infection or disease. Such a response will generally result in the development in the subject of an antibody-mediated and/or a secretory or cellular immune response to the composition.
  • an immunogen e.g., chimeric VP1 protein, VLP, or nucleic acid encoding an antigen
  • such a response includes but is not limited to one or more of the following effects; the production of antibodies from any of the immunological classes, such as immunoglobulins A, D, E, G or M; the proliferation of B and T lymphocytes; the provision of activation, growth and differentiation signals to immunological cells; expansion of helper T cell, suppressor T cell, and/or cytotoxic T cell and/or ⁇ T cell populations.
  • immunological classes such as immunoglobulins A, D, E, G or M
  • B and T lymphocytes the proliferation of B and T lymphocytes
  • the provision of activation, growth and differentiation signals to immunological cells expansion of helper T cell, suppressor T cell, and/or cytotoxic T cell and/or ⁇ T cell populations.
  • an “effective amount” of an adjuvant will be that amount which enhances an immunological response to a coadministered antigen or nucleic acid encoding an antigen.
  • treatment refers to any of (i) the prevention of infection or reinfection or disease, (ii) the reduction or elimination of symptoms, and (iii) the substantial or complete elimination of the pathogen in question. Treatment may be effected prophylactically (prior to infection) or therapeutically (following infection).
  • the present invention is, in part, based on the discovery that all or a portion of the P-domain of the VP1 protein of a first norovirus strain can be replaced with all or the corresponding portion of the P-domain of a second norovirus strain, and that when expressed, such chimeric VP1 proteins can self-assemble into VLPs. It has also been discovered that VLPs that contain any desired VP1 P-domain, even P-domains from VP1 proteins of norovirus strains that are not expressed well in recombinant host cells and therefore do not readily form VLPs.
  • the present invention provides chimeric norovirus VP1 proteins, and norovirus VLPs, that contain all or a portion of any desired P-domain.
  • chimeric norovirus VP1 proteins, and norovirus VLPs, that contain all or a portion of any P-domain, including P-domains from emerging norovirus strains can be produced relatively easily and rapidly.
  • the present invention provides compositions and methods for rapid generation of immunogenic compositions that can be used to induce an immune response in a subject, that preferably can protect the subject from norovirus infection and/or norovirus disease.
  • the invention provides immunogenic compositions comprising chimeric norovirus VP1 protein in the form of monomers or in the form of VLPs.
  • the chimeric norovirus VP1 proteins contain the VP1 S-domain from a first norovirus strain and all or a portion of the VP1 P-domain from a second norovirus strain.
  • the norovirus VLPs of the present invention can be monovalent, and be composed of a single type of chimeric VP1 protein. Such monovalent VLPs contain multiple copies of a single VP1 P-domain from a single norovirus strain. If desired, the norovirus VLP of the present invention can be multivalent, and be composed of two or more different chimeric VP1 proteins. Preferably, the two or more different chimeric VP1 proteins contain the VP1 S-domain from the same norovirus strain, but VP1 P-domains from different norovirus strains.
  • immunogenic compositions of the present invention can further comprise one or more adjuvants or nucleic acids encoding adjuvants, wherein immunogenic polypeptides and/or VLPs are mixed or co-expressed with adjuvants.
  • Immunogenic compositions may also comprise additional antigens other than norovirus antigens, such as antigens that can be used in immunization against pathogens that cause diarrheal diseases.
  • compositions that comprise a nucleic acid molecule that encodes a chimeric norovirus VP1, such as an RNA molecule or a self-replicating RNA molecule.
  • a nucleic acid molecule that encodes a chimeric norovirus VP1 such as an RNA molecule or a self-replicating RNA molecule.
  • Such compositions can be administered to a subject and the encoded chimeric norovirus VP1 can be produced in the subject, preferably in the form of a VLP.
  • nucleic acids including nucleic acids, polypeptides and/or VLPs and methods for their preparation, purification and use in the treatment or prevention of norovirus infection, more detailed discussions are provided below.
  • the chimeric norovirus VP1 protein contains the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.
  • the S-domain and the P-domain of the chimeric norovirus VP1 protein are generally joined through a linker peptide, as they are in naturally occurring VP1 proteins.
  • the linker peptide can allow the chimeric VP1 protein to fold properly, so that it self-assembles to form VLPs.
  • the linker peptide can be any suitable amino acid sequence, such as the linker peptide from the VP1 protein of the first norovirus strain, the second norovirus strain or a third norovirus strain.
  • the first, second, and third norovirus strains can be any desired norovirus strains, such as any of the strains listed in Table 1.
  • the first norovirus strain can be the Snow Mountain strain
  • the second norovirus strain can be any other strain, such as the Norwalk strain or the 2006a strain.
  • amino acid sequence of the S domain, linker and/or P domain of a chimeric VP1 may differ from the corresponding naturally occurring amino acid sequence by one or more amino acid replacement, addition or deletion (e.g., mutation, substitution, insertion, deletion, truncation and the like). Such sequence changes should not prevent the chimeric VP1 proteins from folding properly and self-assembling into VLPs. Generally, it is acceptable for amino acid sequences to vary (including by addition or deletion of one or more amino acids) from naturally occurring sequences in areas that are not highly conserved. For example, as shown in FIGS.
  • amino acid sequence variation can be introduced, if desired, into the amino-terminal region, carboxy-terminal region, and P domain. Some amino acid sequence variations can also be introduced into the S domain and/or P1 subdomain, preferably at nonconserved positions, which are not marked with an asterisk in FIG. 8A .
  • the VP1 proteins of some norovirus strains are difficult to produce in high yields by recombinant expression in host cells, such as yeast.
  • the chimeric norovirus VP1 protein contains an S-domain from a strain that is a high expressor (such as the Snow Mountain strain where expression can be >40 mg per liter of yeast cells) in a desired host cell, such as yeast cells
  • the chimeric protein can be produced in high yield in that host cell even if the P-domain is from a strain that is not well expressed.
  • the secreted soluble expression of Norwalk P-domain can be increased greater than 5-fold by generating a chimeric construct as described with a Snow Mountain S-domain.
  • the chimeric VP1 proteins of the invention can be used to make VLPs that contain the VP1 P-domain from strains that are not well expressed in host cells, and therefore do not readily form VLPs.
  • the S-domain is from the VP1 protein of a strain that is well expressed in a desired host cell, such as yeast cells.
  • the high expressor norovirus strain is a strain whose VP1 protein can be produced recombinantly in a host cell, preferably yeast, in a quantity of at least about 5 mg/liter of cells, at least about 10 mg/liter of cells, at least about 15 mg/liter of cells, at least about 20 mg/liter of cells, at least about 25 mg/liter of cells, at least about 30 mg/liter of cells, at least about 35 mg/liter of cells, or at least about 40 mg/liter of cells.
  • the chimeric norovirus VP1 protein can have a structure according to Formula I:
  • a and B are independently absent or any desired amino acid sequence
  • S is the S-domain of VP1 of a first norovirus strain
  • L is a linker peptide or absent
  • P is a norovirus VP1 P-domain, wherein at least a portion of P is from the P-domain of a second norovirus strain.
  • the linker peptide (L) can be any amino acid sequence that allows the chimeric VP1 protein to fold properly and to self-assemble to form a VLP. Suitable linker peptides include the linker peptide from the VP1 protein of the first norovirus strain, the second norovirus strain or a third norovirus strain. Alternatively, the linker peptide (L) can be a short amino acid sequence that permits the chimeric protein to fold properly and self-assemble into VLPs, e.g., 20 or fewer amino acids (i.e., 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acids), preferably about 9 amino acids.
  • L linker peptides
  • L is the linker peptide from the VP1 protein of the first norovirus strain, the second norovirus strain or a third norovirus strain.
  • a and B when present, are independently any desired amino acid sequence, such as, a sequence of about 1-500 amino acids, about 1-250 amino acids, about 1-100 amino acids, about 1-50 amino acids, about 1-40 amino acids, about 1-30 amino acids, about 1-20 amino acids, about 1-10 amino acids, or about 1-5 amino acids.
  • An epitope tag could consist of a strong T cell epitope or a modified epitope designed to improve the immunogenicity of the protein.
  • a and/or B can comprise immunogenic fragments including, for example, the heat shock proteins or fragments, such as those disclosed in U.S. Publication No. 20060264609, or viral and bacterial antigens, such as those disclosed in U.S. Pat. No. 7,527,801.
  • a and/or B can comprise a full length protein, for example a recombinant protein that is to be displayed on a norovirus VP1 fusion protein, or that is to be used to display norovirus VP1 or portion thereof.
  • a and B are both absent.
  • the P-domain of VP1 comprises a P 1 subdomain and a P 2 subdomain.
  • P can be depicted as P 1 -P 2 , wherein P 1 is the P 1 subdomain and P 2 is the P 2 subdomain.
  • the P 2 subdomain amino acids are inserted into the sequence of the P 1 subdomain amino acids, and the primary structure has the formula P 1 -1-P 2 -P 1 -2, where P 1 -1 is the amino-terminal portion of the sequence of the P 1 subdomain, P 1 -2 is the remainder of the sequence of the P 1 subdomain, and P 2 is the sequence of the P 2 subdomain.
  • the chimeric norovirus VP1 protein can be of Formula I, wherein S is from a first norovirus strain, and P is from a second norovirus strain.
  • L can be any suitable linker, such as the natural linker from the first norovirus strain or the second norovirus strain, or be absent.
  • the chimeric norovirus VP1 protein can contain a P-domain in which a portion of the P-domain is from the same strain as the S domain, and a portion of the P-domain is from a different strain.
  • the portion from the different stain can be the P 1 domain or a portion thereof, the P 2 domain or a portion thereof and any combination of portions of the P 1 domain and the P 2 domain.
  • the portion from the different strain is the P 2 domain or a portion thereof.
  • the chimeric norovirus VP1 protein can have a structure according to Formula II or Formula III.
  • the variables A, S, L and B are as described in Formula I, P 1 is the P 1 domain of VP1 and P 2 is the P 2 domain of VP1, and at least one of P 1 and P 2 is from a norovirus stain different from the strain that provides S.
  • S and P 1 are from a first norovirus stain and P 2 is from a second norovirus strain.
  • S and P 2 are from a first norovirus strain and P 1 is from a second norovirus strain.
  • the linker L if present, can be any suitable linker, such as the linker from the first norovirus strain or the second norovirus strain.
  • the chimeric norovirus VP1 protein is of Formula II wherein S, L and P 1 are from a first norovirus strain and P 2 is from a second norovirus strain.
  • S, L and P 1 are from a first norovirus strain and P 2 is from a second norovirus strain.
  • P 1 is from a first norovirus strain
  • P 2 is from a second norovirus strain.
  • This description of exemplary embodiments encompassed by Formulas II and III is illustrative of chimeric norovirus VP1 proteins that contain a P-domain in which a portion of the P domain is from the same strain as the S domain, and a portion of the P domain is from a different strain.
  • the chimeric norovirus VP1 protein has a structure according to any one of Formulas IV and XVII: S NV -L-P SMV (IV), S SMV -L-P NV (V), S NV -L-P DSV (VI), S SMV -L-P DSV (VII), S NV -L-P GI (VIII), S NV -L-P GII (IX), S NV -L-P GIII (X), S NV -L-P GIV (XI), S NV -L-P GV (XII), S SMV -L-P GI (XIII), S NV -L-P GII (XIV), S SMV -L-P GIII (XV), S SMV -L-P GIV (XVI), S SMV -L-P GV (XVII), where P represents the P-domain, including the P 1 and P 2 subdomains, where the subscript indicates that
  • the chimeric norovirus VP1 protein comprises an S-domain from the VP1 of Snow Mountain strain, the linker peptide from the VP1 of Snow Mountain strain, and a P-domain that contains at least a portion of the P-domain of the VP1 of another norovirus strain.
  • the P-domain or portion thereof is from the VP1 of the Norwalk strain, 2006a strain, or the New La strain.
  • the chimeric norovirus VP1 protein has a primary structure according to Formula XVIII:
  • the subscripts First and Second indicate that the domain is from a first strain or a second strain, respectively.
  • the chimeric norovirus VP1 protein has a primary structure according to any one of Formulas XIX-XLVI: A-S NV -L-P 1 -1 (NV) -P 2 (SMV) -P 1 -2 (NV) -B (XIX), A-S SMV -L-P 1 -1 (SMV) -P2 (NV) -P1-2 (SMV) -B (XX), A-S NV -L-P 1 -1 (NV) -P2 (DSV) -P1-2 (NV) -B (XXI), A-S SMV -L-P 1 -1 (SMV) -P2 (DSV) -P1-2 (SMV) -B (XXII), A-S NV -L-P 1 -1 (SMV) -P2 (DSV) -P1-2 (SMV)
  • a vast number of different chimeric VP1 proteins can be produced by recombinant means using standard procedures.
  • the amino acid sequences of VP1 proteins, and the nucleotide sequences encoding them, from the different strains of norovirus can be obtained from the GenBank database (ncbi.nlm.nih.gov), the Taxonomy Database at National Center for Biotechnology Information (ncbi.nlm.nih.gov) or the PathoSystems Resource Integration Center Database on Caliciviridae (patric.vbi.vt.edu).
  • the chimeric VP1 proteins of the invention When the chimeric VP1 proteins of the invention are produced by expression in a host cell, such as yeast cells, they can self-assemble into VLPs. This is particularly the case for chimeric VP1 proteins that contain an S-domain of VP1 of a norovirus strain that is well expressed in the host cell, such as the S-domain of the Snow Mountain strain.
  • the present invention further provides VLPs that contain a chimeric VP1.
  • the VLPs can be monovalent or bivalent or multivalent. Monovalent VLPs contain a chimeric VP1 protein and only one P-domain. In some embodiments, the monovalent VLP can contain a chimeric VP1 and a naturally occurring VP1 that each contain the same P-domain.
  • Preferred monovalent VLPs are composed of multiple copies (e.g., 180 copies) of a single chimeric VP1 protein. Accordingly, in certain embodiments, the monovalent VLPs of the invention include 180 copies of a single chimeric VP1 of any one of Formulas I-XLVI, for example.
  • Bivalent and multivalent VLPs contain a chimeric VP1 protein and at least 2 different P-domains.
  • a bivalent VLP can contain a chimeric VP1 that contains a first P-domain and a naturally occurring VP1 that contains a second P-domain.
  • the S-domain in the chimeric VP1 and in naturally occurring VP1 is the same.
  • the bivalent or multivalent VLP contains two or more different chimeric VP1 proteins that contain P-domains from different strains.
  • the two or more chimeric VP1 proteins contain the same S-domain.
  • the bivalent or multivalent VLPs of the invention include two or more chimeric VP1 proteins selected from the group consisting of chimeric VP1 proteins according to Formulas I-XLVI, for example.
  • the amino acid sequence of one or both of the S- and P-domains (including P-subdomains) of a chimeric VP1 can be altered (by insertion, deletion, mutation, substitution) to include one or more amino acid insertion(s), deletion(s), mutation(s) or substitution(s) that render the amino acid sequence of the domain or subdomain different from the corresponding naturally occurring amino acid sequence, for example by up to about 20%, up to about 1%, up to about 2%, up to about 3%, up to about 4%, up to about 5%, up to about 10%, up to about 15%, or up to about 20% over the length of the amino acid sequence of the domain or subdomain.
  • the S-domain of the chimeric VP1 protein of the invention can have at least about 70-100% or about 80-100% amino acid sequence identity to a naturally occurring S-domain, including any percent identity within this range, such as at least about 70, at least about 71, at least about 72, at least about 73, at least about 74, at least about 75, at least about 76, at least about 77, at least about 78, at least about 79, at least about 80, at least about 81, at least about 82, at least about 83, at least about 84, at least about 85, at least about 86, at least about 87, at least about 88, at least about 89, at least about 90, at least about 91, at least about 92, at least about 93, at least about 94, at least about 95, at least about 96, at least about 97, at least about 98, at least about 99, or 100% amino acid sequence identity.
  • the P1-1-subdomain of the chimeric VP1 protein of the invention can have at least about 70-100% or about 80-100% amino acid sequence identity relative to a naturally occurring P1-1-subdomain, including any percent identity within this range, such as at least about 70, at least about 71, at least about 72, at least about 73, at least about 74, at least about 75, at least about 76, at least about 77, at least about 78, at least about 79, at least about 80, at least about 81, at least about 82, at least about 83, at least about 84, at least about 85, at least about 86, at least about 87, at least about 88, at least about 89, at least about 90, at least about 91, at least about 92, at least about 93, at least about 94, at least about 95, at least about 96, at least about 97, at least about 98, at least about 99, or 100% amino acid sequence identity.
  • the P 2 -subdomain of the chimeric VP1 protein of the invention can have at least about 70-100% or about 80-100% amino acid sequence identity to a naturally occurring P 2 -subdomain, including any percent identity within this range, such as at least about 70, at least about 71, at least about 72, at least about 73, at least about 74, at least about 75, at least about 76, at least about 77, at least about 78, at least about 79, at least about 80, at least about 81, at least about 82, at least about 83, at least about 84, at least about 85, at least about 86, at least about 87, at least about 88, at least about 89, at least about 90, at least about 91, at least about 92, at least about 93, at least about 94, at least about 95, at least about 96, at least about 97, at least about 98, at least about 99, or 100% amino acid sequence identity.
  • the P1-2-subdomain of the chimeric VP1 protein of the invention can have at least about 70-100% or about 80-100% amino acid sequence identity to a naturally occurring P1-2-subdomain, including any percent identity within this range, such as at least about 70, at least about 71, at least about 72, at least about 73, at least about 74, at least about 75, at least about 76, at least about 77, at least about 78, at least about 79, at least about 80, at least about 81, at least about 82, at least about 83, at least about 84, at least about 85, at least about 86, at least about 87, at least about 88, at least about 89, at least about 90, at least about 91, at least about 92, at least about 93, at least about 94, at least about 95, at least about 96, at least about 97, at least about 98, at least about 99, or 100% amino acid sequence identity.
  • the S-domains of the VP1 proteins of the invention are full-length or near full-length relative to a naturally occurring S-domain. Truncation at either N- or C-terminals or both and internal deletions, are acceptable provided that the ability to form VLPs under conditions that favor VLP formation is preserved. Accordingly, the S-domain may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs and precursor forms of the reference or native S-domain. In some embodiments, the S-domain of the VP1 proteins of the invention is truncated at its N-terminal end by 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues.
  • the S-domain of the VP1 proteins of the invention can be truncated at its C-terminal end by 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues.
  • the S-domain of the VP1 proteins of the invention can contain an internal deletion of 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues in length.
  • the P1-1-subdomains of the VP1 proteins of the invention are full-length or near full-length relative to a naturally occurring P1-1-subdomain, with sequence truncation at either N- or C-terminals or both and/or with internal deletions. Accordingly, the P1-1-subdomain may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs and precursor forms of the naturally occurring P1-1-domain. In some embodiments, the P1-1-subdomain of the VP1 proteins of the invention is truncated at its N-terminal end by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues.
  • the P1-1-subdomain of the VP1 proteins of the invention can be truncated at its C-terminal end by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues.
  • the P1-1-subdomain of the VP1 proteins of the invention can contain an internal deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues in length.
  • the P2-subdomains of the VP1 proteins of the invention are full-length or near full-length relative to the naturally occurring P2-subdomain, with sequence truncation at either N- or C-terminals or both and/or with internal deletions. Accordingly, the P2-subdomain may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs and precursor forms of the naturally occurring P2-domain. In some embodiments, the P2-subdomain of the VP1 proteins of the invention is truncated at its N-terminal end by 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P2-subdomain of the VP1 proteins of the invention can be truncated at its C-terminal end by 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P2-subdomain of the VP1 proteins of the invention can contain an internal deletion of 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P1-2-subdomains of the VP1 proteins of the invention are full-length or near full-length relative to the native or reference P1-2-subdomain, with sequence truncation at either N- or C-terminals or both and/or with internal deletions. Accordingly, the P1-2-subdomain may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs and precursor forms of the naturally occurring P1-2-domain. In some embodiments, the P1-2-subdomain of the VP1 proteins of the invention is truncated at its N-terminal end by 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P1-2-subdomain of the VP1 proteins of the invention can be truncated at its C-terminal end by 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P1-2-subdomain of the VP1 proteins of the invention can contain an internal deletion of 1 to about 26 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 20, 24 or 26 amino acid residues.
  • the P-domains (including P1-1, P2 and P1-2 subdomains) of the chimeric VP1 proteins of the invention can include amino acid sequence insertions or replacements that are portions of other polypeptides, such as polypeptides that are displayed on the chimeric VP1.
  • the P-domain can be fused to another polypeptide or portion of another polypeptide.
  • in Formula 1 B can be an amino acid sequence of another polypeptide that is displayed on the chimeric VP1.
  • the other polypeptide can be displayed on the surface of a VLP that contains the chimeric VP1 protein.
  • the chimeric VP1 proteins of the invention can be produced by expression in suitable recombinant host cells, such as yeast cells, using any suitable methods, including those described herein.
  • the invention further provides recombinant nucleic acids that encode the chimeric norovirus VP1 proteins described herein.
  • These nucleic acids contain a first nucleotide sequence that encodes the S-domain of VP1 of a first norovirus strain, a second nucleotide sequence that encodes a P-domain that contains at least a portion of the P-domain of a second norovirus strain, and optionally, third, forth and fifth nucleotide sequences that encode a linker peptide, and amino acid sequences A and B, respectively.
  • the nucleic acid sequences are operably linked so that the nucleic acid can be transcribed and/or translated to produce a chimeric VP1 protein that self assembles into a VLP.
  • nucleic acid sequences that encode the S-domain and the P-domain of VP1 from desired norovirus strains can be used.
  • nucleic acids that have the same nucleotide sequences as the corresponding sequences in ORF2 in the genome of the desired norovirus strain, or codon optimized variants thereof that are optimized for recombinant expression in a desired host cell, such as yeast cells, can be used.
  • a representative norovirus ORF2 sequence from the Snow Mountain strain is known and is presented in FIG. 4A .
  • the nucleotide sequences of ORF2 of many other norovirus strains are known in the art, such as the ORF2 sequences of Norwalk virus, GenBank Accession No. M87661, Hawaii virus; GenBank Accession No. U07611, and sequences disclosed in the following patent publications: WO 05/030806, WO 00/79280, JP2002020399, US2003129588, U.S. Pat. No. 6,572,862, WO 94/05700, and WO 05/032457. See also Green et al. (2000) J. Infect. Dis. 181(Suppl.
  • nucleotide sequences of noroviruses can be obtained from the GenBank database (ncbi.nlm.nih.gov), the Taxonomy Database at National Center for Biotechnology Information (ncbi.nlm.nih.gov) or the PathoSystems Resource Integration Center Database on Caliciviridae (patric.vbi.vt.edu).
  • the recombinant nucleic acids encode a chimeric VP1 protein described herein, such as a chimeric VP1 protein according to Formula I.
  • the recombinant nucleic acid can include a coding sequence according to Formula LIV
  • A′ and B′ are independently absent or a nucleotide sequence encoding any desired amino acid sequence
  • S′ is a nucleotide sequence encoding the S-domain of VP1 of a first norovirus strain
  • L′ is absent or a nucleotide sequence encoding a linker peptide and
  • P′ is a nucleotide sequence encoding a norovirus VP1 P-domain, wherein at least a portion of P is from the P-domain of a second norovirus strain.
  • linker peptide encoded by L′ and the amino acid sequences encoded by A′, S′, P′ and B′ are as described herein for L, A, S, P, and B, respectively.
  • the recombinant nucleic acid contains a coding sequence that encodes a chimeric VP1 protein according to any one of Formulas I-XLVI.
  • the recombinant nucleic acid contains a coding sequence that encodes a chimeric VP1 protein have any of the primary structures shown in FIG. 7 .
  • FIGS. 5 and 6 Representative recombinant nucleic acids that encode chimeric VP1 proteins that contain the S-sequence from Snow Mountain strain and the P-sequence from Norwalk stain; or the S-sequence from Snow Mountain strain and the P-sequence from GII.4 2006a.OPTI.P strain are shown in FIGS. 5 and 6 respectively.
  • the S-domain encompasses residues 1-216 and the linker includes residues 217 to 226.
  • the P-sequence encompassed residues 231-530.
  • the P-sequence encompassed residues 227-541.
  • Additional representative norovirus sequences are Norwalk virus, GenBank Accession No.
  • a nucleic acid encoding a chimeric VP1 protein can be RNA or DNA, can be constructed using any suitable method (e.g. by chemical synthesis, using recombinant DNA technology) and can take various forms (e.g. single stranded, double stranded, vectors, etc.). Many suitable methods for producing recombinant constructs are well-known and conventional in the art.
  • the recombinant nucleic acids can be produced from two or more oligonucleotides comprising sequences encoding portions of the chimeric VP1 protein or by ligating oligonucleotides to form a coding sequence for the full-length chimeric VP1 protein using standard molecular biology techniques.
  • nucleic acids are prepared in substantially pure form (i.e. substantially free from other host cell or non host cell nucleic acids).
  • Polynucleotides that encode VP1 proteins of interest can be isolated from a genomic library derived from viral RNA, present in, for example, stool or vomit samples from an infected individual.
  • norovirus nucleic acids can be isolated from infected humans or other mammals or from stool or vomit samples collected from infected individuals as described in e.g., Estes et al. U.S. Pat. No. 6,942,865; Guntapong et al. (2004) Jpn J. Infect. Dis. 57:276-278; Harrington et al. (2004) J. Virol. 78:3035-3045; Fankhauser et al. (1998) J. Infect. Dis. 178:1571-1578; and Dolin et al.
  • Porcine viruses can be grown in LLC-PK cells in the presence of intestinal fluid containing bile acids (Chang et al. (2004) Proc. Natl. Acad. Sci. U.S.A. 101:8733-8738).
  • An amplification method such as PCR can be used to amplify polynucleotides from either norovirus genomic RNA or cDNA encoding therefore.
  • polynucleotides can be chemically synthesized.
  • the nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired.
  • synthetic constructs will contain codons optimized for expression in the intended host cell in which the chimeric VP1 protein will be produced.
  • the complete sequence of the polynucleotide of interest can be assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) Nature 292:756; Nambair et al. (1984) Science 223:1299; Jay et al. (1984) J. Biol. Chem. 259:6311; Stemmer et al. (1995) Gene 164:49-53.
  • the polynucleotides can be RNA or single- or double-stranded DNA.
  • the polynucleotides are isolated free of other components, such as proteins and lipids.
  • nucleotide sequences can be obtained from vectors harboring the desired sequences or synthesized completely or in part using various oligonucleotide synthesis techniques known in the art, such as site-directed mutagenesis and polymerase chain reaction (PCR) techniques where appropriate. See, e.g., Sambrook, supra.
  • PCR polymerase chain reaction
  • one method of obtaining nucleotide sequences encoding the desired sequences is by annealing complementary sets of overlapping synthetic oligonucleotides, followed by ligation with an appropriate DNA ligase and amplification of the ligated nucleotide sequence via PCR. See, e.g., Jayaraman et al. (1991) Proc. Natl. Acad. Sci.
  • oligonucleotide directed synthesis Jones et al. (1986) Nature 54:75-82
  • oligonucleotide directed mutagenesis of pre-existing nucleotide regions Riechmann et al. (1988) Nature 332:323-327 and Verhoeyen et al. (1988) Science 239:1534-1536
  • enzymatic filling-in of gapped oligonucleotides using T4 DNA polymerase Queen et al. (1989) Proc. Natl. Acad. Sci. USA 86:10029-10033
  • Recombinant constructs encoding chimeric VP1 proteins can be prepared in suitable vectors, such as expression vectors, using conventional methods.
  • the recombinant construct such as an expression vector, includes a nucleic acid sequence which encodes a chimeric norovirus VP1 protein.
  • the recombinant construct can be in the form of DNA, RNA, and can be either single or double stranded.
  • the construct can be in the form of a plasmid.
  • a number of suitable vectors for expression of recombinant proteins in a desired host cell are well-known and conventional in the art.
  • Suitable vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, a terminator), and/or one or more translation signals; and a signal sequence or leader sequence for targeting to the secretory pathway in a selected host cell (e.g., of mammalian origin or from a heterologous mammalian or non-mammalian species).
  • a suitable baculovirus expression vector such as pFastBac (Invitrogen) is used to produce recombinant baculovirus particles.
  • the baculovirus particles are amplified and used to infect insect cells to express recombinant protein.
  • a vector that will drive expression of the construct in the desired mammalian host cell e.g., Chinese hamster ovary cells
  • yeast a vector that will drive expression in the desired yeast host cell (e.g., Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenual polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica ) is used.
  • Viral vectors can be used for the production of VLPs of the invention in eukaryotic cells, such as those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. Additionally, a vaccinia based infection/transfection system, as described in Tomei et al. (1993) J. Virol. 67:4017-4026 and Selby et al. (1993) J. Gen. Virol. 74:1103-1113, will also find use with the present invention. In this system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase.
  • This polymerase displays extraordinar specificity in that it only transcribes templates bearing T7 promoters.
  • cells are transfected with the DNA of interest, driven by a T7 promoter.
  • the polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into protein by the host translational machinery.
  • T7 can be added as a purified protein or enzyme as in the “Progenitor” system (Studier and Moffatt (1986) J. Mol. Biol. 189:113-130).
  • the method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation product(s).
  • the recombinant nucleic acids can be in the form of, or components of, a vectored expression system, such as a self-replicating nucleic acid molecule (e.g., RNA), an alphavirus particle, an alphavirus replicon, and the like.
  • a vectored expression system such as a self-replicating nucleic acid molecule (e.g., RNA), an alphavirus particle, an alphavirus replicon, and the like.
  • the vector can include a detectable marker.
  • the detectable marker can be a polypeptide that confers resistance to one or more antibiotics. Additional information about the vectors of the invention is provided below in section C.
  • VLPs Viral-Like Particles
  • the invention further provides recombinant host cells that contain a nucleic acid that encodes a chimeric norovirus VP1 protein, and methods for producing a chimeric norovirus VP1 protein and VLPs that contain the chimeric VP1 protein.
  • the chimeric VP1 proteins can be produced using any suitable method.
  • recombinant constructs that encode the chimeric VP1 protein in suitable recombinant host cells, such as insect cells (e.g., Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda , and Trichoplusia ni ), mammalian cells (e.g., human, non-human primate, horse, cow, sheep, dog, cat, and rodent (e.g., hamster), avian cells (e.g., chicken, duck, and geese, bacteria (e.g., E.
  • insect cells e.g., Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda , and Trichoplusia ni
  • mammalian cells e.g., human, non-human primate, horse, cow
  • yeast cells e.g., Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenual polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yarrowia lipolytica
  • Tetrahymena cells e.g., Tetrahymena thermophila
  • Many suitable insect cells and mammalian cells are well-known in the art.
  • Suitable insect cells include, for example, Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and High Five cells (a clonal isolate derived from the parental Trichoplusia ni BTI-TN-5B1-4 cell line (Invitrogen)).
  • Suitable mammalian cells include, for example, Chinese hamster ovary (CHO) cells, human embryonic kidney cells (HEK293 cells, typically transformed by sheared adenovirus type 5 DNA), NIH-3T3 cells, 293-T cells, Vero cells, HeLa cells, PERC.6 cells (ECACC deposit number 96022940), Hep G2 cells, MRC-5 (ATCC CCL-171), WI-38 (ATCC CCL-75), fetal rhesus lung cells (ATCC CL-160), Madin-Darby bovine kidney (“MDBK”) cells, Madin-Darby canine kidney (“MDCK”) cells (e.g., MDCK (NBL2), ATCC CCL34; or MDCK 33016, DSM ACC 2219), baby hamster kidney (BHK) cells, such as BHK21-F, HKCC cells, and the like.
  • CHO Chinese hamster ovary
  • HEK293 cells human embryonic kidney cells
  • Suitable avian cells include, for example, chicken embryonic stem cells (e.g., EBx® cells), chicken embryonic fibroblasts, chicken embryonic germ cells, duck cells (e.g., AGE1.CR and AGE1.CR.pIX cell lines (ProBioGen) which are described, for example, in Vaccine 27:4975-4982 (2009) and WO2005/042728), EB66 cells, and the like.
  • chicken embryonic stem cells e.g., EBx® cells
  • chicken embryonic fibroblasts e.g., chicken embryonic germ cells
  • duck cells e.g., AGE1.CR and AGE1.CR.pIX cell lines (ProBioGen) which are described, for example, in Vaccine 27:4975-4982 (2009) and WO2005/042728
  • EB66 cells e.g., EB66 cells, and the like.
  • Suitable insect cell expression systems such as baculovirus systems, are known to those of skill in the art and described in, e.g., Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego Calif. Avian cell expression systems are also known to those of skill in the art and described in, e.g., U.S. Pat. Nos. 5,340,740; 5,656,479; 5,830,510; 6,114,168; and 6,500,668; European Patent No. EP 0787180B; European Patent Publication No.
  • yeast, bacterial and mammalian cell expression systems are also known in the art and described in, e.g., Yeast Genetic Engineering (Barr et al., eds., 1989) Butterworths, London.
  • the method for producing a chimeric norovirus VP1 protein comprises culturing a host cell transformed with a recombinant nucleic acid that encodes a chimeric VP1 protein under conditions suitable for expression of the nucleic acid, whereby a chimeric norovirus VP1 protein is produced.
  • Chimeric VP1 proteins can self-assemble to form VLPs, and preferably the host cell is maintained under conditions suitable for VLP formation. Conditions suitable for the formation of VLPs are well known and easily determined by a person of ordinary skill in the art. See, e.g., U.S. Pat. No.
  • the method can further include the step of isolating or purifying the chimeric norovirus VP1 protein, VLPs containing the chimeric VP1 protein, or a combination thereof from the culture media or cells.
  • the host cell used to produce the chimeric VP1 protein and/or VLPs containing the chimeric VP1 protein is a yeast cell, insect cell, or a combination thereof.
  • Multivalent VLPs can be prepared by maintaining a host cell that contains recombinant nucleic acids encoding two different chimeric VLPs. For example, this can be accomplished using a bicistronic expression vector, such as pCDC.7 for expression in yeast.
  • a bicistronic expression vector such as pCDC.7 for expression in yeast.
  • two or more monovalent VLPs can be prepared, and optionally purified, and then mixed to produce a formulation of VLPs that is multivalent.
  • the norovirus chimeric VP1 proteins, and VLPs can also be produced by expression of a recombinant nucleic acid molecule that encodes a norovirus chimeric VP1 proteins, e.g., in the form of or as a component of a vectored expression system, by the cells of a mammal following administration of the recombinant nucleic acid to the mammal
  • the present invention further provides a method of isolating or purifying norovirus VLPs from culture media, host cells or a combination thereof.
  • the VLPs are isolated or purified directly from the host cell culture media, i.e., conditioned culture media.
  • the host cells can be recovered, for example by centrifugation, a host cell homogenate or lysate can be formed using any suitable methods, and VLPs can be isolated. Suitable chemical, physical or mechanical means, which lyse the cells yet keep the VLPs substantially intact are known in the art and are described in, e.g., Protein Purification Applications: A Practical Approach, (E. L. V. Harris and S. Angal, Eds., 1990).
  • VLPs can be isolated from culture media or host cells, e.g., a cell lysate or homogenate, using any suitable method. Suitable methods that maintain the integrity of VLPs, such as, density gradient centrifugation, e.g., sucrose gradients, PEG-precipitation, pelleting, and the like (see, e.g., Kirnbauer et al. (1993) J. Virol. 67:6929-6936), as well as standard purification techniques including, e.g., ion exchange and gel filtration chromatography can be used. Centrifugation, on a sucrose cushion or sucrose gradient is convenient method for isolating VLPs from VP1 monomers or oligomers and from other cellular components.
  • density gradient centrifugation e.g., sucrose gradients, PEG-precipitation, pelleting, and the like
  • standard purification techniques including, e.g., ion exchange and gel filtration chromatography can be used.
  • VLPs that are purified on a sucrose cushion or gradient can then be further purified if desired, for example, using ion exchange chromatography, size exclusion chromatography or any other suitable method.
  • norovirus virus-like particles VLPs can be purified from the media of yeast cells expressing the norovirus VP1 protein. A low speed spin (15,000 ⁇ g) can be performed on the media to remove extra cells or cellular debris. Following this step a high speed spin (100,000 ⁇ g) through a 40% sucrose cushion can be performed to separate the virus-like particles from free protein and other material.
  • the pellet containing the VLPs can be resuspended in buffer (50 mM Tris pH 7.5, 100 mM NaCl) and loaded onto an ion exchange column.
  • the VLPs can be eluted from the column using a salt gradient.
  • the eluted fractions containing the VLPs can be concentrated and buffer exchanged into a lower salt buffer (20 mM Tris pH 7.5, 100 mM NaCl) and stored at 4° Celsius until needed.
  • the invention also provides immunogenic compositions comprising one or more chimeric VP1 proteins, preferably in the form of a VLP. Two or more different chimeric VP1 proteins, monovalent VLPs, or multivalent VLPs may be mixed together to produce a multivalent immunogenic composition that contains two or more different VP1 P-domains.
  • the immunogenic compositions may comprise a mixture of chimeric VP1 proteins, VLPs and nucleic acids, which in turn may be delivered using the same or different vehicles.
  • Antigens may be administered individually or in combination, in e.g., prophylactic (i.e., to prevent infection) or therapeutic (to treat infection) immunogenic compositions.
  • the immunogenic composition may be given more than once (e.g., a “prime” administration followed by one or more “boosts”) to achieve the desired effects.
  • the same composition can be administered in one or more priming and one or more boosting steps. Alternatively, different compositions can be used for priming and boosting.
  • the immunogenic composition may further comprise one or more other antigens, from a norovirus or from another pathogen, if desired.
  • a combination immunogenic composition can contain a norovirus VLP that comprises a chimeric VP1 protein and one or more antigens from another pathogen, such as a bacterial, viral or fungal pathogen.
  • the immunogenic composition of the invention can comprise a norovirus VLP that comprises a chimeric VP1 protein as described herein, and one or more rotavirus antigens such as a live attenuated rotavirus (e.g., ROTARIX (rotavirus vaccine, live, oral; GlaxoSmithKline)), one or more live reassortant rotaviruses (e.g., ROTATEQ (rotavirus vaccine, live, oral, pentavalent; Merck), ROTASHIELD (rotavirus vaccine, live, oral, tetravalent; Wyeth-Lederle)), non-human rotaviruses (e.g., lamb (Lanzhou), bovine, rhesus), reassortant rotaviruses (e.g., human-bovine, human-lamb, human-rhesus), inactivated rotavirus (e.g., heat inactivated), rotavirus subunits (e.g.,
  • the immunogenic composition comprises a recombinant nucleic acid molecule that encodes a norovirus chimeric VP1 protein.
  • such immunogenic compositions can contain a suitable nucleic acid delivery system, such as liposomes, lipoplexes, emulsions (nanoemulsions, microemulsions), particles (nanoparticles, microparticles), a vector, such as a viral particle, a replicon, and the like.
  • the immunogenic compositions generally include one or more “pharmaceutically acceptable excipients or vehicles” such as water, saline, glycerol, ethanol, and the like singly or in combination
  • Immunogenic compositions will typically, in addition to the components mentioned above, comprise one or more “pharmaceutically acceptable carriers.” These include any carrier which does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers typically are large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art.
  • auxiliary substance such as a wetting or emulsifying agent, pH buffering substance, and the like, may be present.
  • auxiliary substance such as a wetting or emulsifying agent, pH buffering substance, and the like.
  • compositions of the invention for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, proprionates, malonates, or benzoates.
  • mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates
  • organic acids such as acetates, proprionates, malonates, or benzoates.
  • antigens can be adsorbed to, entrapped within or otherwise associated with liposomes and particulate carriers such as poly(D,L-lactide co-glycolide) (PLG) microparticles or nanoparticles.
  • PLG poly(D,L-lactide co-glycolide)
  • Antigens can be conjugated to a carrier protein in order to enhance immunogenicity. See Ramsay et al. (2001) Lancet 357(9251):195-196; Lindberg (1999) Vaccine 17 Suppl 2:S28-36; Buttery & Moxon (2000) J R Coll Physicians Lond 34:163-168; Ahmad & Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii; Goldblatt (1998) J. Med. Microbiol.
  • Immunogenic compositions of the present invention may be administered in conjunction with other immunoregulatory agents.
  • an immunogenic composition of the invention can include an adjuvant.
  • Preferred adjuvants include, but are not limited to, one or more of the following types of adjuvants described below.
  • Immunogenic compositions of the present invention may also be pre-mixed with an adjuvant before administration.
  • the adjuvant for use in the present invention is alum (aluminum potassium sulfate (AlK(SO 4 ) 2 )), or an alum derivative, such as that formed in-situ by mixing an antigen in phosphate buffer with alum, followed by titration and precipitation with a base such as ammonium hydroxide or sodium hydroxide.
  • alum aluminum potassium sulfate (AlK(SO 4 ) 2 )
  • AlK(SO 4 ) 2 aluminum potassium sulfate
  • alum derivative such as that formed in-situ by mixing an antigen in phosphate buffer with alum, followed by titration and precipitation with a base such as ammonium hydroxide or sodium hydroxide.
  • the adjuvant for use in the present invention is retinoic acid, the oxidized form of Vitamin A, with only partial vitamin A function.
  • the adjuvant for use in the present invention is MF59C.1, an oil-in-water emulsion (squalene) in citrate buffer.
  • MF59C.1 has been shown to be an effective adjuvant and enhance the production of high titers of neutralizing antibodies against parvovirus B19 (Ballou et al. (2003) JID, 187:675-678).
  • Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminum salts and calcium salts.
  • suitable mineral salts include hydroxides (e.g. oxyhydroxides), phosphates (e.g. hydroxyphosphates, orthophosphates), sulfates, etc. (e.g. see chapters 8 & 9 of Vaccine Design . . . (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.), or mixtures of different mineral compounds (e.g. a mixture of a phosphate and a hydroxide adjuvant, optionally with an excess of the phosphate), with the compounds taking any suitable form (e.g. gel, crystalline, amorphous, etc.), and with adsorption to the salt(s) being preferred.
  • the mineral containing compositions may also be formulated as a particle of metal salt (WO00/23105).
  • aluminium hydroxide typically aluminium oxyhydroxide salts, which are usually at least partially crystalline.
  • Aluminium oxyhydroxide which can be represented by the formula AlO(OH)
  • AlO(OH) 3 aluminium hydroxide
  • IR infrared
  • the degree of crystallinity of an aluminum hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes.
  • WHH half height
  • the surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption.
  • a fibrous morphology e.g. as seen in transmission electron micrographs
  • the pI of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH. Adsorptive capacities of between 1.8-2.6 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium hydroxide adjuvants.
  • the adjuvants known as “aluminium phosphate” are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt.
  • Hydroxyphosphates generally have a PO 4 /Al molar ratio between 0.3 and 1.2. Hydroxyphosphates can be distinguished from strict AlPO 4 by the presence of hydroxyl groups. For example, an IR spectrum band at 3164 cm ⁇ 1 (e.g. when heated to 200° C.) indicates the presence of structural hydroxyls [ch. 9 of Vaccine Design . . . (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.].
  • the PO 4 /Al 3+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95 ⁇ 0.1.
  • the aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts.
  • a typical adjuvant is amorphous aluminium hydroxyphosphate with PO 4 /Al molar ratio between 0.84 and 0.92, included at 0.6 mg Al 3+ /ml.
  • the aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5-20 ⁇ m (e.g. about 5-10 ⁇ m) after any antigen adsorption.
  • Adsorptive capacities of between 0.7-1.5 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
  • Suspensions of aluminium salts used to prepare compositions of the invention may contain a buffer (e.g. a phosphate or a histidine or a Tris buffer), but this is not always necessary.
  • the suspensions are preferably sterile and pyrogen-free.
  • a suspension may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 20 mM, preferably between 5 and 15 mM, and more preferably about 10 mM.
  • the suspensions may also comprise sodium chloride.
  • an adjuvant component includes a mixture of both an aluminium hydroxide and an aluminium phosphate.
  • there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2:1 e.g. ⁇ 5:1, ⁇ 6:1, ⁇ 7:1, ⁇ 8:1, ⁇ 9:1, etc.
  • the concentration of Al +++ in a composition for administration to a patient is preferably less than 10 mg/ml e.g. ⁇ 5 mg/ml, ⁇ 4 mg/ml, ⁇ 3 mg/ml, ⁇ 2 mg/ml, ⁇ 1 mg/ml, etc.
  • a preferred range is between 0.3 and 1 mg/ml.
  • a maximum of ⁇ 0.85 mg/dose is preferred.
  • Oil emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59 [Chapter 10 of Vaccine Design . . . (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.] (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer). Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) may also be used.
  • CFA Complete Freund's adjuvant
  • IFA incomplete Freund's adjuvant
  • oil-in-water emulsions typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible.
  • the oil droplets in the emulsion are generally less than 5 ⁇ m in diameter, and advantageously the emulsion comprises oil droplets with a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220 nm are preferred as they can be subjected to filter sterilization.
  • the invention can be used with oils such as those from an animal (such as fish) or vegetable source.
  • Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils.
  • Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used.
  • 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils.
  • Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention.
  • the procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art.
  • Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein.
  • a number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids.
  • Shark liver oil contains a branched, unsaturated terpenoid known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene.
  • Other preferred oils are the tocopherols (see below). Oil in water emulsions comprising sqlauene are particularly preferred. Mixtures of oils can be used.
  • Surfactants can be classified by their ‘HLB’ (hydrophile/lipophile balance). Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16.
  • the invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAXTM tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy(oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol
  • Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
  • detergents such as Tween 80 may contribute to the thermal stability seen in the examples below.
  • surfactants can be used e.g. Tween 80/Span 85 mixtures.
  • a combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable.
  • Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
  • Preferred amounts of surfactants are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1%, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20%, preferably 0.1 to 10% and in particular 0.1 to 1% or about 0.5%.
  • polyoxyethylene sorbitan esters such as Tween 80
  • octyl- or nonylphenoxy polyoxyethanols such as Triton X-100, or other detergents in the Triton series
  • polyoxyethylene ethers such as laureth 9
  • oil-in-water emulsion adjuvants useful with the invention include, but are not limited to:
  • Antigens (VLPs) and adjuvants in a composition will typically be in admixture at the time of delivery to a patient.
  • the emulsions may be mixed with antigen (VLP) during manufacture, or extemporaneously, at the time of delivery.
  • the adjuvant and antigen (VLP) may be kept separately in a packaged or distributed vaccine, ready for final formulation at the time of use.
  • the antigen (VLP) will generally be in an aqueous form, such that the vaccine is finally prepared by mixing two liquids.
  • the volume ratio of the two liquids for mixing can vary (e.g. between 5:1 and 1:5) but is generally about 1:1.
  • Saponin formulations may also be used as adjuvants in the invention.
  • Saponins are a heterogeneous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the Quillaia saponaria Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria officianalis (soap root).
  • Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. QS21 is marketed as StimulonTM.
  • Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C.
  • the saponin is QS21.
  • a method of production of QS21 is disclosed in U.S. Pat. No. 5,057,540.
  • Saponin formulations may also comprise a sterol, such as cholesterol.
  • ISCOMs immunostimulating complexes
  • a phospholipid such as phosphatidylethanolamine or phosphatidylcholine.
  • Any known saponin can be used in ISCOMs.
  • the ISCOM includes one or more of QuilA, QHA & QHC. ISCOMs are further described in WO96/33739.
  • the ISCOMS may be devoid of additional detergent.
  • VLPs Virosomes And Virus Like Particles
  • Virosomes and virus-like particles can also be used as adjuvants in the invention.
  • These structures generally contain one or more proteins from a virus optionally combined or formulated with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome.
  • the viral proteins may be recombinantly produced or isolated from whole viruses.
  • viral proteins suitable for use in virosomes or VLPs include proteins derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, QB-phage (such as coat proteins), GA-phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein p1).
  • influenza virus such as HA or NA
  • Hepatitis B virus such as core or capsid proteins
  • Hepatitis E virus measles virus
  • Sindbis virus Rotavirus
  • Foot-and-Mouth Disease virus Retrovirus
  • Norwalk virus Norwalk virus
  • human Papilloma virus HIV
  • RNA-phages such as coat proteins
  • GA-phage f-phage
  • fr-phage AP
  • Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as non-toxic derivatives of enterobacterial lipopolysaccharide (LPS), Lipid A derivatives, immunostimulatory oligonucleotides and ADP-ribosylating toxins and detoxified derivatives thereof.
  • LPS enterobacterial lipopolysaccharide
  • Lipid A derivatives Lipid A derivatives
  • immunostimulatory oligonucleotides and ADP-ribosylating toxins and detoxified derivatives thereof.
  • Non-toxic derivatives of LPS include monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL).
  • 3dMPL is a mixture of 3 de-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains.
  • a preferred “small particle” form of 3 De-O-acylated monophosphoryl lipid A is disclosed in EP-A-0689454. Such “small particles” of 3dMPL are small enough to be sterile filtered through a 0.22 ⁇ m membrane (EP-A-0689454).
  • Other non-toxic LPS derivatives include monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g. RC-529.
  • Lipid A derivatives include derivatives of lipid A from Escherichia coli such as OM-174.
  • OM-174 is described for example in Meraldi et al. (2003) Vaccine 21:2485-2491 and Pajak et al. (2003) Vaccine 21:836-842.
  • Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention include nucleotide sequences containing a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked by a phosphate bond to a guanosine). Double-stranded RNAs and oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be immunostimulatory.
  • the CpG's can include nucleotide modifications/analogs such as phosphorothioate modifications and can be double-stranded or single-stranded.
  • References Kandimalla et al. (2003) Nucleic Acids Research 31:2393-2400; WO02/26757, and WO99/62923 disclose possible analog substitutions e.g. replacement of guanosine with 2′-deoxy-7-deazaguanosine.
  • the adjuvant effect of CpG oligonucleotides is further discussed in Krieg (2003) Nature Medicine 9:831-835; McCluskie et al. (2002) FEMS Immunology and Medical Microbiology 32:179-185; WO98/40100; U.S. Pat. No. 6,207,646; U.S. Pat. No. 6,239,116; and U.S. Pat. No. 6,429,199.
  • the CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT (Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658).
  • the CpG sequence may be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it may be more specific for inducing a B cell response, such a CpG-B ODN.
  • CpG-A and CpG-B ODNs are discussed in Blackwell et al. (2003) J Immunol 170:4061-4068; Krieg (2002) Trends Immunol 23:64-65 and WO01/95935.
  • the CpG is a CpG-A ODN.
  • the CpG oligonucleotide is constructed so that the 5′ end is accessible for receptor recognition.
  • two CpG oligonucleotide sequences may be attached at their 3′ ends to form “immunomers”. See, for example, Kandimalla et al. (2003) Biochemical Society Transactions 31 (part 3):654-658 & Kandimalla et al. (2003) BBRC 306:948-953; Bhagat et al. (2003) BBRC 300:853-861 and WO03/035836.
  • an adjuvant used with the invention may comprise a mixture of (i) an oligonucleotide (e.g. between 15-40 nucleotides) including at least one (and preferably multiple) CpI motifs (i.e. a cytosine linked to an inosine to form a dinucleotide), and (ii) a polycationic polymer, such as an oligopeptide (e.g. between 5-20 amino acids) including at least one (and preferably multiple) Lys-Arg-Lys tripeptide sequence(s).
  • an oligonucleotide e.g. between 15-40 nucleotides
  • CpI motifs i.e. a cytosine linked to an inosine to form a dinucleotide
  • a polycationic polymer such as an oligopeptide (e.g. between 5-20 amino acids) including at least one (and preferably multiple) Lys-Arg-Lys tripeptide sequence(s).
  • the oligonucleotide may be a deoxynucleotide comprising 26-mer sequence 5′-(IC) 13 -3′ (SEQ ID NO:9).
  • the polycationic polymer may be a peptide comprising 11-mer amino acid sequence KLKLLLLLKLK (SEQ ID NO:10).
  • Bacterial ADP-ribosylating toxins and detoxified derivatives thereof may be used as adjuvants in the invention.
  • the protein is derived from E. coli ( E. coli heat labile enterotoxin “LT”), cholera (“CT”), or pertussis (“PT”).
  • LT E. coli heat labile enterotoxin
  • CT cholera
  • PT pertussis
  • the use of detoxified ADP-ribosylating toxins as mucosal adjuvants is described in WO95/17211 and as parenteral adjuvants in WO98/42375.
  • the toxin or toxoid is preferably in the form of a holotoxin, comprising both A and B subunits.
  • the A subunit contains a detoxifying mutation; preferably the B subunit is not mutated.
  • the adjuvant is a detoxified LT mutant such as LT-K63, LT-R72, and LT-G192.
  • LT-K63 LT-R72
  • LT-G192 LT-G192.
  • ADP-ribosylating toxins and detoxified derivatives thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in Beignon et al. (2002) Infect Immun 70:3012-3019; Pizza et al. (2001) Vaccine 19:2534-2541; Pizza et al. (2000) Int J Med Microbiol 290:455-461; Scharton-Kersten et al. (2000) Infect Immun 68:5306-5313; Ryan et al. (1999) Infect Immun 67:6270-6280; Partidos et al.
  • a useful CT mutant is or CT-E29H.
  • Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in Domenighini et al. (1995) Mol Microbiol 15:1165-1167, specifically incorporated herein by reference in its entirety.
  • Human immunomodulators suitable for use as adjuvants in the invention include cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.) (WO99/40936 and WO99/44636), interferons (e.g. interferon- ⁇ ), macrophage colony stimulating factor, and tumor necrosis factor.
  • cytokines such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.) (WO99/40936 and WO99/44636), interferons (e.g. interferon- ⁇ ), macrophage colony stimulating factor, and tumor necrosis factor.
  • interferons e.g. interferon- ⁇
  • macrophage colony stimulating factor e.g. interferon- ⁇
  • tumor necrosis factor e.g. interferon- ⁇
  • Bioadhesives and mucoadhesives may also be used as adjuvants in the invention.
  • Suitable bioadhesives include esterified hyaluronic acid microspheres (Singh et al. (2001) J. Cont. Release 70:267-276) or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof may also be used as adjuvants in the invention (WO99/27960).
  • Microparticles may also be used as adjuvants in the invention.
  • Microparticles i.e. a particle of ⁇ 100 nm to ⁇ 150 ⁇ m in diameter, more preferably 200 nm to ⁇ 30 ⁇ m in diameter, and most preferably ⁇ 500 nm to ⁇ 10 ⁇ m in diameter
  • materials that are biodegradable and non-toxic e.g. a poly( ⁇ -hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.
  • a negatively-charged surface e.g. with SDS
  • a positively-charged surface e.g. with a cationic detergent, such as CTAB
  • liposome formulations suitable for use as adjuvants are described in U.S. Pat. No. 6,090,406, U.S. Pat. No. 5,916,588 and EP A 0626169.
  • Adjuvants suitable for use in the invention include polyoxyethylene ethers and polyoxyethylene esters (WO99/52549). Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152).
  • Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-steoryl ether, polyoxytheylene-8-steoryl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.
  • PCPP Polyphosphazene
  • PCPP formulations are described, for example, in Andrianov et al. (1998) Biomaterials 19:109-115 and Payne et al. (1998) Adv Drug Delivery Review 31:185-196.
  • muramyl peptides suitable for use as adjuvants in the invention include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • nor-MDP N-acetyl-normuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-
  • imidazoquinolone compounds suitable for use as adjuvants in the invention include Imiquamod and its homologues (e.g. “Resiquimod 3M”), described further in Stanley (2002) Clin Exp Dermatol 27:571-577 and Jones (2003) Curr Opin Investig Drugs 4:214-218.
  • benzonaphthyridine compounds suitable for use as adjuvants in the invention are described in WO 2009/111337.
  • Lipopeptides i.e., compounds comprising one or more fatty acid residues and two or more amino acid residues
  • Lipopeptides based on glycerylcysteine are particularly suitable for use as adjuvants in the invention. Specific examples of such peptides include compounds of the following formula:
  • each of R 1 and R 2 represents a saturated or unsaturated, aliphatic or mixed aliphatic-cycloaliphatic hydrocarbon radical having from 8 to 30, preferably 11 to 21, carbon atoms that is optionally also substituted by oxygen functions
  • R 3 represents hydrogen or the radical R 1 —CO—O—CH 2 — in which R 1 has the same meaning as above
  • X represents an amino acid bonded by a peptide linkage and having a free, esterified or amidated carboxy group, or an amino acid sequence of from 2 to 10 amino acids of which the terminal carboxy group is in free, esterified or amidated form.
  • the amino acid sequence comprises a D-amino acid, for example, D-glutamic acid (D-Glu) or D-gamma-carboxy-glutamic acid (D-Gla).
  • TLR 2 Bacterial lipopeptides generally recognize TLR 2 , without requiring TLR 6 to participate.
  • TLRs operate cooperatively to provide specific recognition of various triggers, and TLR2 plus TLR6 together recognize peptidoglycans, while TLR2 recognizes lipopeptides without TLR6.
  • TLR2 recognizes lipopeptides without TLR6.
  • Synthetic lipopeptides tend to behave similarly, and are primarily recognized by TLR2.
  • Lipopeptides suitable for use as adjuvants in the invention include compounds with the following formula:
  • each R 1a and R 1b is independently an aliphatic or cycloaliphatic-aliphatic hydrocarbon group having 7-21 carbon atoms, optionally substituted by oxygen functions, or one of R 1a and R 1b , but not both, is H;
  • R 2 is an aliphatic or cycloaliphatic hydrocarbon group having 1-21 carbon atoms and optionally substituted by oxygen functions;
  • n 0 or 1
  • Kw is an aliphatic hydrocarbon group having 1-12 carbon atoms
  • As 1 is a D- or L-alpha-amino acid
  • Z 1 and Z 2 each independently represent —OH or the N-terminal radical of a D- or L-alpha amino acid of an amino-(lower alkane)-sulfonic acid or of a peptide having up to 6 amino acids selected from the D- and L-alpha aminocarboxylic acids and amino-lower alkyl-sulfonic acids; and
  • Z 3 is H or —CO—Z 4 , where Z 4 is —OH or the N-terminal radical of a D- or L-alpha amino acid of an amino-(lower alkane)-sulfonic acid or of a peptide having up to 6 amino acids selected from the D and L-alpha aminocarboxylic acids and amino-lower alkyl-sulfonic acids; or an ester or amide formed from the carboxylic acid of such compounds.
  • Suitable amides include —NH 2 and NH(lower alkyl), and suitable esters include C1-C4 alkyl esters. (lower alkyl or lower alkane, as used herein, refers to C 1 -C 6 straight chain or branched alkyls).
  • lipopeptide compound suitable for use as an adjuvant in the invention is a lipopeptide with the following formula:
  • LP40 lipopeptide species
  • TLR 2 Another example of a lipopeptide species is called LP40, and is an agonist of TLR 2 .
  • murein lipoproteins These are related to a known class of lipopeptides from E. coli , referred to as murein lipoproteins. Certain partial degradation products of those proteins called murein lipopeptides are described in Hantke et al. (1973) Eur. J. Biochem., 34: 284-296. These comprise a peptide linked to N-acetyl muramic acid and are thus related to Muramyl peptides, which are described in Baschang, et al., Tetrahedron (1989) 45(20): 6331-6360.
  • the invention may also comprise combinations of aspects of one or more of the adjuvants identified above.
  • the following adjuvant compositions may be used in the invention: (1) a saponin and an oil-in-water emulsion (WO99/11241); (2) a saponin (e.g. QS21)+a non-toxic LPS derivative (e.g. 3dMPL) (WO94/00153); (3) a saponin (e.g. QS21)+a non-toxic LPS derivative (e.g. 3dMPL)+a cholesterol; (4) a saponin (e.g.
  • QS21)+3dMPL+IL-12 (optionally+a sterol) (WO98/57659); (5) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions (European patent applications 0835318, 0735898 and 0761231); (6) SAF, containing 10% squalane, 0.4% Tween 80TM, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion; (7) RibiTM adjuvant system (RAS), (Ribi Immunochem) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DetoxTM); and (8) one or more mineral salt
  • the invention is an immunogenic composition that contains a parvovirus VLP that contains VP1 and VP2, as described herein, and an adjuvant, such as MF59.
  • VLP and the adjuvant e.g, MF59
  • MF59 can be premixed and provided as a single composition, or can be provided as separate components that are to be mixed prior to administration.
  • compositions of the invention will generally be administered directly to a patient.
  • Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or mucosally, such as by rectal, oral (e.g. tablet, spray), vaginal, topical, transdermal (See e.g. WO99/27961) or transcutaneous (See e.g. WO02/074244 and WO02/064162), intranasal (See e.g.
  • Transdermal delivery can be achieved, for example, using microneedles
  • Immunogenic compositions can also be administered topically by direct transfer to the surface of the skin. Topical administration can be accomplished without utilizing any devices, or by contacting naked skin with the immunogenic composition utilizing a bandage or a bandage-like device (see, e.g., U.S. Pat. No. 6,348,450).
  • the mode of administration is parenteral, mucosal or a combination of mucosal and parenteral immunizations. Even more preferably, the mode of administration is parenteral, mucosal or a combination of mucosal and parenteral immunizations in a total of 1-2 vaccinations 1-3 weeks apart.
  • the route of administration includes but is not limited to oral delivery, intra-muscular delivery and a combination of oral and intramuscular delivery.
  • the method for treating or preventing an infection by a norovirus comprises mucosally administering to a subject in need thereof a first immunogenic composition comprising one or more norovirus antigens followed by parenterally administering a therapeutically effective amount of a second immunogenic composition comprising one or more norovirus antigens.
  • the immunogenic composition may be used to elicit systemic and/or mucosal immunity, preferably to elicit an enhanced systemic and/or mucosal immunity.
  • the immune response is characterized by the induction of a serum IgG and/or intestinal IgA immune response.
  • prime-boost methods are preferably employed where one or more gene delivery vectors and/or polypeptide antigens are delivered in a “priming” step and, subsequently, one or more second gene delivery vectors and/or polypeptide antigens are delivered in a “boosting” step.
  • priming and boosting with one or more gene delivery vectors or polypeptide antigens described herein is followed by additional boosting with one or more polypeptide-containing compositions (e.g., polypeptides comprising norovirus antigens).
  • the various compositions can be delivered in any order.
  • the nucleic acids need not be all delivered before the polypeptides.
  • the priming step may include delivery of one or more polypeptides and the boosting comprises delivery of one or more nucleic acids and/or one or more polypeptides.
  • Multiple polypeptide administrations can be followed by multiple nucleic acid administrations or polypeptide and nucleic acid administrations can be performed in any order.
  • one or more of the gene delivery vectors described herein and one or more of the polypeptides described herein can be co-administered in any order and via any administration route. Therefore, any combination of polynucleotides and polypeptides described herein can be used to elicit an immune reaction.
  • Dosage treatment can be according to a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and/or in a booster immunization schedule. In a multiple dose schedule, the various doses may be given by the same or different routes, e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc.
  • routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc.
  • the dosage regime enhances the avidity of the antibody response leading to antibodies with a neutralizing characteristic.
  • Chimeric norovirus VP1 proteins and VLPs as described above can be administered to a mammal, such as a mouse, baboon, chimpanzee, or human, to activate norovirus-specific T cells in vivo.
  • Administration can be by any means known in the art, including parenteral, intranasal, intramuscular or subcutaneous injection, including injection using a biological ballistic gun, as discussed above.
  • a composition of the invention comprising a chimeric norovirus VP1 protein or VLP is administered in a manner compatible with the particular composition used and in an amount which is effective to induce an immune response (e.g., a T cell response and/or a humoral response), preferably a protective immune response.
  • an immune response e.g., a T cell response and/or a humoral response
  • Norovirus-specific T cell responses can be measured by, inter alia, a 51Cr release assay, a lymphoproliferation assay, or by intracellular staining for IFN- ⁇ .
  • the proteins can be administered either to a mammal which is not infected with a norovirus or can be administered to a norovirus-infected mammal.
  • the particular dosages of the fusion proteins in a composition will depend on many factors including, but not limited to, the species, age, and general condition of the mammal to which the composition is administered, and the mode of administration of the composition. An effective amount of the composition of the invention can be readily determined using only routine experimentation. In vitro and in vivo models can be employed to identify appropriate doses.
  • a norovirus polypeptide or VLP will be administered to a large mammal, such as a baboon, chimpanzee, or human.
  • co-stimulatory molecules or adjuvants can also be provided before, after, or together with the compositions.
  • compositions of the invention may be given in a single dose schedule, or preferably in a multiple dose schedule in which a primary course of vaccination includes 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and/or reinforce an immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose or doses after several months.
  • One way of checking efficacy of therapeutic treatment involves monitoring infection after administration of the compositions of the invention.
  • Another way of checking efficacy of prophylactic treatment involves monitoring immune responses both systemically (such as monitoring the level of IgG1 and IgG2a production) and mucosally (such as monitoring the level of IgA production) against the antigens in the compositions of the invention after administration of the composition.
  • serum specific antibody responses are determined post-immunization but pre-challenge whereas mucosal specific antibody responses are determined post-immunization and post-challenge.
  • Another way of assessing the immunogenicity of the component proteins of the immunogenic compositions of the present invention is to express the proteins recombinantly and to screen patient sera or mucosal secretions by immunoblot. A positive reaction between the protein and the patient serum indicates that the patient has previously mounted an immune response to the protein in question—that is, the protein is an immunogen. This method may also be used to identify immunodominant proteins and/or epitopes.
  • In vivo efficacy models include a human challenge model, which is supported by the NIH and the Center for Disease Control (CDC) (see for example, Lindesmith et al. (2003) Nat. Med. 9: 548-553 and Lindesmith et al. (2005) J. Virol. 79: 2900-2909).
  • CDC Center for Disease Control
  • the immune response may be one or both of a TH1 immune response and a TH2 response.
  • the immune response may be an improved or an enhanced or an altered immune response.
  • the immune response may be one or both of a systemic and a mucosal immune response.
  • Preferably the immune response is an enhanced systemic and/or mucosal response.
  • an enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response.
  • the enhanced immune response includes an increase in the production of IgG1 and/or IgG2a and/or IgA.
  • the mucosal immune response is a TH2 immune response.
  • the mucosal immune response includes an increase in the production of IgA.
  • Activated TH2 cells enhance antibody production and are therefore of value in responding to extracellular infections.
  • Activated TH2 cells may secrete one or more of IL-4, IL-5, IL-6, and IL-10.
  • a TH2 immune response may result in the production of IgG1, IgE, IgA and memory B cells for future protection.
  • a TH2 immune response may include one or more of an increase in one or more of the cytokines associated with a TH2 immune response (such as IL-4, IL-5, IL-6 and IL-10), or an increase in the production of IgG1, IgE, IgA and memory B cells.
  • the enhanced TH2 immune response will include an increase in IgG1 production.
  • a TH1 immune response may include one or more of an increase in CTLs, an increase in one or more of the cytokines associated with a TH1 immune response (such as IL-2, IFN ⁇ , and TNF ⁇ ), an increase in activated macrophages, an increase in NK activity, or an increase in the production of IgG2a.
  • the enhanced TH1 immune response will include an increase in IgG2a production.
  • Immunogenic compositions of the invention in particular, immunogenic composition comprising one or more antigens of the present invention may be used either alone or in combination with other antigens optionally with an immunoregulatory agent capable of eliciting a Th1 and/or Th2 response.
  • the invention also comprises an immunogenic composition
  • an immunogenic composition comprising one or more immunoregulatory agents, such as a mineral salt, such as an aluminium salt and an oligonucleotide containing a CpG motif.
  • the immunogenic composition includes both an aluminium salt and an oligonucleotide containing a CpG motif.
  • the immunogenic composition includes an ADP ribosylating toxin, such as a detoxified ADP ribosylating toxin and an oligonucleotide containing a CpG motif.
  • the one or more immunoregulatory agents include an adjuvant.
  • the adjuvant may be selected from one or more of the group consisting of a TH1 adjuvant and TH2 adjuvant, further discussed above.
  • the immunogenic compositions of the invention will preferably elicit both a cell mediated immune response as well as a humoral immune response in order to effectively address an infection.
  • This immune response will preferably induce long lasting (e.g., neutralizing) antibodies and a cell mediated immunity that can quickly respond upon exposure to one or more infectious antigens.
  • the invention also provides a composition of the invention for use as a medicament, in particular for making or for use as a vaccine.
  • the medicament is preferably able to raise an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine.
  • the invention also provides the use of the compositions of the invention in the manufacture of a medicament for raising an immune response in a mammal.
  • the medicament is preferably a vaccine.
  • the vaccine is used to prevent and/or treat an intestinal infection such as gastroenteritis, preferably acute gastroenteritis.
  • the gastroenteritis may result from an imbalance in ion and/or water transfer resulting in both watery diarrhea and/or intestinal peristalisis and/or motility.
  • the gastroenteritis may also result in vomiting.
  • the invention provides methods for inducing or increasing an immune response using the compositions described above.
  • the immune response is preferably protective and can include antibodies and/or cell-mediated immunity (including systemic and mucosal immunity). Immune responses include booster responses.
  • the invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention.
  • the immune response is preferably protective and preferably involves antibodies and/or cell-mediated immunity.
  • the immune response includes one or both of a TH1 immune response and a TH2 immune response. The method may raise a booster response.
  • the mammal is preferably a human.
  • the immunogenic composition preferably a vaccine
  • the human is preferably a child (e.g. an infant or toddler, pre-schooler, such as a child one year or less, from one to three, or four, or five, or six, or seven, or eight, or nine, or ten years onwards), a teenager, an elderly person (e.g., about 60 years old or older) or a person in a high risk group, such as military personnel, travelers, healthcare workers, child care (day care) providers, and food handlers.
  • the immunogenic composition or vaccine can also be administered to such individuals for therapeutic use.
  • a vaccine intended for children may also be administered to adults (e.g. to assess safety, dosage, immunogenicity, etc.).
  • target groups for the immunogenic compositions (e.g., vaccines) of the present invention include: transplant and immunocompromised individuals; adults and children in, e.g., USA, Canada and Europe including but not limited to the following: food handlers; healthcare workers such as but not limited to hospital and nursing home personnel; day care providers; travelers, including cruise ship travelers; military personnel; and pediatric and/or elderly populations as discussed above.
  • Norovirus-specific T cells which are activated by the chimeric VP1 proteins or VLPs expressed in vivo or in vitro, preferably recognize an epitope of the P-domain of the VP1.
  • Norovirus-specific T cells can be CD8+ or CD4+.
  • Norovirus-specific CD8+ T cells can be cytotoxic T lymphocytes (CTL) which can kill norovirus-infected cells that display any of these epitopes complexed with an MHC class I molecule.
  • CTL cytotoxic T lymphocytes
  • Norovirus-specific CD8+ T cells can be detected by, for example, 51Cr release assays. 51Cr release assays measure the ability of norovirus-specific CD8+ T cells to lyse target cells displaying one or more of these epitopes.
  • Norovirus-specific CD8+ T cells which express antiviral agents, such as IFN- ⁇ , are also contemplated herein and can also be detected by immunological methods, preferably by intracellular staining for IFN- ⁇ or like cytokine after in vitro stimulation with one or more of the norovirus polypeptides, such as those described herein.
  • Norovirus-specific CD4+ T cells can be detected by a lymphoproliferation assay. Lymphoproliferation assays measure the ability of norovirus-specific CD4+ T cells to proliferate in response to, e.g., a VP1.
  • the chimeric norovirus VP1 proteins and VLPs can be used to activate norovirus-specific T cells either in vitro or in vivo. Activation of norovirus-specific T cells can be used, inter alia, to provide model systems to optimize CTL responses to norovirus and to provide prophylactic or therapeutic treatment against norovirus infection.
  • proteins are preferably supplied to T cells via a plasmid or a viral vector, such as an adenovirus vector, as described above.
  • Polyclonal populations of T cells can be derived from the blood, and preferably from peripheral lymphoid organs, such as lymph nodes, spleen, or thymus, of mammals that have been infected with a norovirus. Preferred mammals include mice, chimpanzees, baboons, and humans. Infection with norovirus serves to expand the number of activated norovirus-specific T cells in the mammal.
  • the norovirus-specific T cells derived from the mammal can then be restimulated in vitro by adding, a norovirus immunogenic polypeptide, and/or fusion protein according to the present invention.
  • the norovirus-specific T cells can then be tested for, inter alia, proliferation, the production of IFN- ⁇ , and the ability to lyse target cells displaying, for example, VP1 polypeptide epitopes in vitro.
  • kits comprising one or more containers of immunogenic compositions of the invention.
  • Compositions can be in liquid form or can be lyophilized, as can individual antigens.
  • Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.
  • Containers can be formed from a variety of materials, including glass or plastic.
  • a container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery device.
  • a pharmaceutically-acceptable buffer such as phosphate-buffered saline, Ringer's solution, or dextrose solution.
  • the kit may further include a third component comprising an adjuvant.
  • the kit can also comprise a package insert containing written instructions for methods of inducing immunity or for treating infections.
  • the package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
  • FDA Food and Drug Administration
  • the invention also provides a delivery device pre-filled with the immunogenic compositions of the invention.
  • Constructs for production of chimeric norovirus VP1 proteins, and VLPs containing the chimeric proteins, Saccharomyces cerevisiae strain AD3 were created by cloning sequences encoding chimeric VP1 proteins into the yeast expression vector pBS24.1.
  • the pBS24.1 vector is described in detail in commonly owned U.S. patent application Ser. No. 382,805, filed Jul. 19, 1989, which application is hereby incorporated by reference in its entirety herein.
  • the pBS24.1 vector contains the 2-micron sequence for autonomous replication in yeast and the yeast genes leu2d and URA3 as selectable markers.
  • the ⁇ -lactamase gene and the ColE1 origin of replication, required for plasmid replication in bacteria, are also present in this expression vector. Regulation of expression was put under the control of a hybrid ADH2/GAPDH promoter (described in U.S. Pat. No. 6,183,985) and an alpha-factor terminator.
  • the constructs were created and utilized for expression of Snow Mountain (SMV0/Norwalk VP1 proteins included the polynucleotide sequence shown in FIG. 6 (SEQ ID NO:16). To do that, a fragment corresponding to the S-domain of the a previously generated Snow Mountain gene, excised by restriction enzymes HindIII and Acc651, was ligated to a fragment corresponding to the P-domain of Norwalk gene that was generated using restriction enzymes Alw211 and Sal1. This new chimeric DNA was ligated into a pMADCS subcloning vector ( FIG. 1 ) at the HindIII-SalI site and amplified. The amplified fragment (shown in FIG.
  • expression vector pBS24.1 was used in production of Snow Mountain/GII.4.2006a VLPs (SMV/GII.4.2006a/chimeras) in Saccharomyces cerevisiae strain AD3.
  • the coding sequence that was utilized for the expression of chimeric SMV/GII.4.2006a VP1 proteins is shown in FIG. 7 .
  • the coding sequence was generated using synthetic oligonucleotides, based on the cDNA sequences of VP1 S- and P-domains of Snow Mountain and GII.4.2006a viruses.
  • S. cerevisiae strain AD3 (MATa, leu2, ura3-52, prb1-1122, pep4-3, prc1-407, gal2, [cir0], ::pDM15(pGAP/ADR1::G418R), ::Yip5 ⁇ leuAD) was transformed with the expression plasmids described above. Before the transformation, the yeast cells were streaked on YEPD (yeast extract bactopeptone 2% glucose) plates and a single colony was selected for preparation of competent cells for transformation.
  • YEPD yeast extract bactopeptone 2% glucose
  • Yeast transformation was performed using the Invitrogen S.c. EasyCompTM Transformation Kit. After transformation, several Ura-transformants were streaked onto Ura-8% glucose plates in order to obtain single colonies. The single colonies were subsequently patched onto Leu-8% glucose plates to increase the plasmid copy number.
  • Leu-starter cultures were grown for 24 hours at 30° C. and then diluted 1:20 in YEPD (yeast extract bactopeptone 2% glucose) or Veggie (Novagen Veggie Peptone and Veggie Yeast Extract) media. Cells were grown for 48-72 hours at 30° C. to allow depletion of the glucose in the media and then harvested. Induction occurred upon depletion of glucose from the media. This system provided a high cell mass before the foreign genes were induced.
  • VLPs Norovirus virus-like particles
  • a low speed spin (15,000 ⁇ g) was performed on the media to remove extra cells or cellular debris.
  • the supernatant was subjected to a four hour high speed spin (100,000 ⁇ g) through a 40% sucrose cushion to separate the virus-like particles from free protein and other material.
  • the pellet containing the VLPs was resuspended in buffer (50 mM Tris pH 7.5, 100 mM NaCl) and loaded onto a CaptoTM Q column and eluted with high salt.
  • the VLPs were eluted from the column during a gradient of increasing salt.
  • the eluted fraction containing the VLPs were concentrated and buffer exchanged into a lower salt buffer (20 mM Tris pH 7.5, 100 mM NaCl) and stored at 4° C. until use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US13/808,157 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods Abandoned US20130171185A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/808,157 US20130171185A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36158110P 2010-07-06 2010-07-06
US13/808,157 US20130171185A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods
PCT/US2011/042979 WO2012006293A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/042979 A-371-Of-International WO2012006293A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/946,324 Continuation US10065994B2 (en) 2010-07-06 2015-11-19 Norovirus derived immunogenic compositions and methods

Publications (1)

Publication Number Publication Date
US20130171185A1 true US20130171185A1 (en) 2013-07-04

Family

ID=44628871

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/808,157 Abandoned US20130171185A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods
US14/946,324 Active US10065994B2 (en) 2010-07-06 2015-11-19 Norovirus derived immunogenic compositions and methods
US16/053,399 Active US10287324B2 (en) 2010-07-06 2018-08-02 Norovirus derived immunogenic compositions and methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/946,324 Active US10065994B2 (en) 2010-07-06 2015-11-19 Norovirus derived immunogenic compositions and methods
US16/053,399 Active US10287324B2 (en) 2010-07-06 2018-08-02 Norovirus derived immunogenic compositions and methods

Country Status (8)

Country Link
US (3) US20130171185A1 (enrdf_load_stackoverflow)
EP (2) EP3153578A1 (enrdf_load_stackoverflow)
JP (3) JP2013533745A (enrdf_load_stackoverflow)
CN (1) CN103154242B (enrdf_load_stackoverflow)
AU (1) AU2011276328C1 (enrdf_load_stackoverflow)
CA (1) CA2804501C (enrdf_load_stackoverflow)
MX (1) MX2013000163A (enrdf_load_stackoverflow)
WO (1) WO2012006293A1 (enrdf_load_stackoverflow)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140193484A1 (en) * 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
US20140227346A1 (en) * 2011-07-06 2014-08-14 Andrew Geall Immunogenic combination compositions and uses thereof
US20140271712A1 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US20180161458A1 (en) * 2015-06-12 2018-06-14 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
WO2017160124A3 (ko) * 2016-03-18 2018-08-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
WO2018144216A1 (en) * 2017-01-31 2018-08-09 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
WO2018182983A1 (en) * 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
KR101914779B1 (ko) 2016-03-18 2018-11-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
US10752946B2 (en) 2017-01-31 2020-08-25 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
US11232850B2 (en) 2017-03-24 2022-01-25 Myriad Genetics, Inc. Copy number variant caller
US20220125723A1 (en) 2010-07-06 2022-04-28 Glaxosmithkline Biologicals Sa Lipid formulations with viral immunogens
US11596645B2 (en) 2010-07-06 2023-03-07 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11608361B2 (en) * 2017-03-23 2023-03-21 Medicago Inc. Norovirus fusion proteins and VLPS comprising norovirus fusion proteins
US11639370B2 (en) 2010-10-11 2023-05-02 Glaxosmithkline Biologicals Sa Antigen delivery platforms
US11655475B2 (en) 2010-07-06 2023-05-23 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11708574B2 (en) 2016-06-10 2023-07-25 Myriad Women's Health, Inc. Nucleic acid sequencing adapters and uses thereof
US11759422B2 (en) 2010-08-31 2023-09-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding RNA
US11854666B2 (en) 2016-09-29 2023-12-26 Myriad Women's Health, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization
US12076388B2 (en) 2017-11-30 2024-09-03 Aramis Biotechnologies Inc. Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins
US20250269007A1 (en) * 2016-05-04 2025-08-28 CureVac SE Nucleic acid molecules and uses thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145245A2 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US20160038586A1 (en) * 2014-08-07 2016-02-11 Medigen Biotechnology Corp. Virus-like Particle Vaccines
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
CA3106471A1 (en) 2018-07-13 2020-01-16 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
MX2021011059A (es) * 2019-03-12 2021-10-13 Icon Genetics Gmbh Particulas tipo norovirus con estabilidad mejorada.
EP4087604A4 (en) * 2020-01-08 2023-11-01 Bharat Biotech International Limited COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS
CN114316033A (zh) * 2020-09-29 2022-04-12 香港理工大学深圳研究院 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用
CN115161343B (zh) * 2021-04-01 2024-06-04 苏州相奕生物技术有限公司 一种重组腺病毒表达载体及以其制备的多价诺如病毒疫苗
KR20240111822A (ko) * 2021-10-27 2024-07-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 노로바이러스 백신 및 사용 방법
JPWO2023176206A1 (enrdf_load_stackoverflow) 2022-03-18 2023-09-21
WO2024144262A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gi mrna를 포함하는 백신 조성물
WO2024144272A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gii mrna를 포함하는 백신 조성물
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081447A2 (en) * 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
BR9405957A (pt) 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2001524533A (ja) 1997-12-02 2001-12-04 パウダージェクト ヴァクシンズ，インコーポレイテッド 粒子状ワクチン組成物の経皮的送達
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
EP1053015A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2002538770A (ja) 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
ES2398413T3 (es) 1999-06-22 2013-03-19 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Kit de detección de SRSV
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ES2505700T3 (es) 2000-06-01 2014-10-10 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados
ES2288969T3 (es) 2000-06-15 2008-02-01 Novartis Vaccines And Diagnostics, Inc. Inmunoensayos para anticuerpos anti-hcv.
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002064162A2 (en) 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
AU2002252378B2 (en) 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
WO2003068925A2 (en) 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1500699A1 (en) 2003-07-22 2005-01-26 Vivalis Production of vaccinia virus with adherent or non adherent avian cell lines
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20050266550A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
US9150882B2 (en) 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
KR20100083150A (ko) 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
CN101153341B (zh) * 2007-09-21 2010-12-15 珠海市疾病预防控制中心 诺如病毒gⅱ型检测用引物、检测方法、检测试剂盒
AU2009222105B2 (en) 2008-03-03 2012-05-17 Novartis Ag Compounds and compositions as TLR activity modulators
WO2010006238A2 (en) 2008-07-11 2010-01-14 The Administrators Of The Tulane Educational Fund Stimulus-responsive apta-chelamers
NO2324113T3 (enrdf_load_stackoverflow) * 2008-08-08 2018-07-28
WO2010033736A1 (en) 2008-09-17 2010-03-25 Xencor, Inc. Novel compositons and methods for treating ige-mediated disorders
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2370463B1 (en) 2008-11-26 2016-08-31 Amgen Inc. A stabilized variant of activin iib receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081447A2 (en) * 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pierre et al., XP055009042 - AERES report on the research unit Agents pathogènes et inflammation From the University of Franche-Comté; PROJECT Team 3, 2010:pdf pages 1-21. *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11596645B2 (en) 2010-07-06 2023-03-07 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11773395B1 (en) 2010-07-06 2023-10-03 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
US11766401B2 (en) 2010-07-06 2023-09-26 Glaxosmithkline Biologicals Sa Methods of administering lipid formulations with immunogens
US12186333B2 (en) 2010-07-06 2025-01-07 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11913001B2 (en) 2010-07-06 2024-02-27 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11905514B2 (en) 2010-07-06 2024-02-20 Glaxosmithkline Biological Sa Immunisation of large mammals with low doses of RNA
US11759475B2 (en) 2010-07-06 2023-09-19 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11891608B2 (en) 2010-07-06 2024-02-06 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
US11883534B2 (en) 2010-07-06 2024-01-30 Glaxosmithkline Biologicals Sa Immunisation with lipid formulations with RNA encoding immunogens
US11865080B2 (en) 2010-07-06 2024-01-09 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11857681B2 (en) 2010-07-06 2024-01-02 Glaxosmithkline Biologicals Sa Lipid formulations with RNA encoding immunogens
US11857562B2 (en) 2010-07-06 2024-01-02 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11851660B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US20220125723A1 (en) 2010-07-06 2022-04-28 Glaxosmithkline Biologicals Sa Lipid formulations with viral immunogens
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens
US11690861B2 (en) 2010-07-06 2023-07-04 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11730754B2 (en) 2010-07-06 2023-08-22 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11717529B2 (en) 2010-07-06 2023-08-08 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11786467B2 (en) 2010-07-06 2023-10-17 Glaxosmithkline Biologicals Sa Lipid formulations with immunogens
US11638694B2 (en) 2010-07-06 2023-05-02 Glaxosmithkline Biologicals Sa Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
US11638693B2 (en) 2010-07-06 2023-05-02 Glaxosmithkline Biologicals Sa Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids
US11655475B2 (en) 2010-07-06 2023-05-23 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11666534B2 (en) 2010-07-06 2023-06-06 Glaxosmithkline Biologicals Sa Methods of administering lipid formulations with viral immunogens
US11690862B1 (en) 2010-07-06 2023-07-04 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11690864B2 (en) 2010-07-06 2023-07-04 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11690865B2 (en) 2010-07-06 2023-07-04 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11690863B2 (en) 2010-07-06 2023-07-04 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11739334B2 (en) 2010-07-06 2023-08-29 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11839686B2 (en) 2010-07-06 2023-12-12 Glaxosmithkline Biologicals Sa Lipid formulations with viral immunogens
US11696923B2 (en) 2010-07-06 2023-07-11 Glaxosmithkline Biologicals, Sa Delivery of RNA to trigger multiple immune pathways
US11707482B2 (en) 2010-07-06 2023-07-25 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
US11759422B2 (en) 2010-08-31 2023-09-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding RNA
US11639370B2 (en) 2010-10-11 2023-05-02 Glaxosmithkline Biologicals Sa Antigen delivery platforms
US20140227346A1 (en) * 2011-07-06 2014-08-14 Andrew Geall Immunogenic combination compositions and uses thereof
US11896636B2 (en) * 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US20140193484A1 (en) * 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
US9975923B2 (en) * 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US20140271712A1 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US11433146B2 (en) * 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
US20180161458A1 (en) * 2015-06-12 2018-06-14 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
US12186407B2 (en) 2015-06-12 2025-01-07 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
EP3307239B1 (en) 2015-06-12 2020-09-16 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
KR101915740B1 (ko) 2016-03-18 2018-11-06 (주)인테라 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
WO2017160124A3 (ko) * 2016-03-18 2018-08-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
KR101914779B1 (ko) 2016-03-18 2018-11-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
US20250269007A1 (en) * 2016-05-04 2025-08-28 CureVac SE Nucleic acid molecules and uses thereof
US11708574B2 (en) 2016-06-10 2023-07-25 Myriad Women's Health, Inc. Nucleic acid sequencing adapters and uses thereof
US11854666B2 (en) 2016-09-29 2023-12-26 Myriad Women's Health, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization
US10752946B2 (en) 2017-01-31 2020-08-25 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
US10968447B2 (en) 2017-01-31 2021-04-06 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
WO2018144216A1 (en) * 2017-01-31 2018-08-09 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
US11339431B2 (en) 2017-01-31 2022-05-24 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
US11987601B2 (en) 2017-03-23 2024-05-21 Aramis Biotechnologies Inc. Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
US11608361B2 (en) * 2017-03-23 2023-03-21 Medicago Inc. Norovirus fusion proteins and VLPS comprising norovirus fusion proteins
US11232850B2 (en) 2017-03-24 2022-01-25 Myriad Genetics, Inc. Copy number variant caller
WO2018182983A1 (en) * 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
US12076388B2 (en) 2017-11-30 2024-09-03 Aramis Biotechnologies Inc. Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins

Also Published As

Publication number Publication date
EP2591097A1 (en) 2013-05-15
US20190023746A1 (en) 2019-01-24
CN103154242A (zh) 2013-06-12
US10287324B2 (en) 2019-05-14
JP2018086020A (ja) 2018-06-07
MX2013000163A (es) 2013-03-05
JP2016053087A (ja) 2016-04-14
CA2804501C (en) 2021-01-26
AU2011276328C1 (en) 2016-01-21
AU2011276328A1 (en) 2013-02-28
JP6351641B2 (ja) 2018-07-04
US10065994B2 (en) 2018-09-04
AU2011276328B2 (en) 2015-07-09
CN103154242B (zh) 2015-09-30
US20160222066A1 (en) 2016-08-04
CA2804501A1 (en) 2012-01-12
EP3153578A1 (en) 2017-04-12
JP2013533745A (ja) 2013-08-29
WO2012006293A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
US10287324B2 (en) Norovirus derived immunogenic compositions and methods
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
US9744228B2 (en) Method for generating a parvovirus B19 virus-like particle
EP2360175B1 (en) Norovirus and Sapovirus virus-like particles (VLPs)
Kamili Toward the development of a hepatitis E vaccine
Li et al. Lessons from hepatitis E vaccine design
CN102712930A (zh) 猪细环病毒的疫苗和诊断
WO2011126976A1 (en) Reovirus vaccines and methods of use therefor
WO2013030608A1 (en) Nanoparticle-based veterinary vaccine
KR20190023604A (ko) 바이러스 유사입자 기반의 복합백신
WO2023083964A1 (en) Parvovirus structural protein against beta- and gamma-hpv
CN111778219A (zh) 展示南非2型口蹄疫病毒b细胞表位猪细小病毒样颗粒的制备方法
Entry Cross-Linking of Rotavirus Outer Capsid

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS, INC.;REEL/FRAME:030141/0138

Effective date: 20130401

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., CALIFORNI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SETTEMBRE, ETHAN;MEDINA-SELBY, ANGELICA;COIT, DORIS;AND OTHERS;SIGNING DATES FROM 20130305 TO 20130311;REEL/FRAME:030141/0009

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION